Method for generating replication defective viral vectors that are helper free

ABSTRACT

Sequences are provided that are capable of directing circular adeno-associated virus replication, useful in vectors for providing therapeutic agents to a subject in need thereof. The vectors of the invention are particularly useful in the treatment of acute medical conditions requiring rapid gene expression. Further provided are methods for producing packaged defective viral vectors.

RELATIONSHIP TO OTHER PATENT APPLICATIONS

This application claims priority to U.S. provisional applications60/294,797 filed 31 May 2001, and 60/313,007 filed 17 Aug. 2001, both ofwhich applications are herein specifically incorporated by reference intheir entirety.

FIELD OF THE INVENTION

The present invention provides a method of producing defective viralvectors for gene therapy that are completely free of helper viralvectors and helper viruses. The invention further provides new circularAAV vectors which are particularly useful for use in gene therapy andproduction stocks of packaged defective viral vectors.

BACKGROUND

Gene therapy is likely to become the most significant development inmedicine of our time. However, before gene therapy becomes a standardmedical procedure, certain technical problems common to all methods ofgene delivery must be overcome. One key obstacle is the currentinability to produce large quantities of pure replication defectiveviral vectors.

Indeed, most gene therapy protocols use replication defective viralvectors as gene therapy vehicles. This is due to the ability of virusesto efficiently transfect their own DNA into a host cell. By replacingviral genes that are needed for the replication (the non-essentialgenes) with heterologous genes of interest, replication defective viralvectors can transduce the host cell and thereby provide the desiredgenetic material to the host cell. The non-essential genes can beprovided in trans in order to produce the replication defective viralvectors. Thus the non-essential genes are placed into the genome of thepackaging cell line, on a plasmid, or a helper virus. A number ofreplication defective viral vectors have been constructed, though mostof the work has centered on three particular DNA viruses; theadenovirus, the adeno-associated virus and the herpes simplex virus type1.

Adeno-associated virus type 2 (AAV) is a human non-pathogenic parvoviruswith a genome of approximately 4.7 kb. The AAV genome consists of twoORFs that encode regulatory (Rep) and structural capsid (Cap) proteinsflanked by 145-bp inverted terminal repeats (ITR). These ITRs are theonly cis-acting elements necessary for virus replication andencapsidation. Recombinant AAVs (rAAV) which do not contain anyendogenous coding regions efficiently propagate when Rep and Cap areprovided in trans. In nature, a secondary infection with helper virus,e.g. adenovirus, is necessary to trigger a productive infection. AAVgenomes then undergo replication followed by assembly of infectiousvirions containing ssDNA of either (+) or (−) polarity. Adenovirus genesimplicated in AAV replication have been identified and include E1A, E1B,E4orf6, E2A, and VA RNA.

Similar to provirus in latently infected cells, AAV genomes can beefficiently rescued from a recombinant cis-plasmid following transienttransfection into human cells. The necessary helper functions can bedelivered either by adenovirus infection or by transfecting a plasmidencoding a minimal set of adenovirus helper genes (Collaco et al. Gene238:397-405).

Events of AAV lytic infection are described by a commonly acceptedself-priming strand-displacement model. The first 125 nucleotides of AAVtermini include elements capable of forming a T-shaped duplex structure(A′-B′-B-C′-C-A) and are followed by a unique 20 by D-sequence (Wang etal. (1995) J. Mol. Biol. 250:573-580). The Rep gene encodes fourproteins that are synthesized from the same ORF via the use of alternatepromoters and splicing. Two of these proteins (Rep78 and Rep68) possesssite-specific and strand-specific endonuclease activity. They bind tothe Rep-binding site (Rbs) mapped to the tetrameric GAGC repeat of theA-stem of the ITR and cleave it at the terminal resolution site (trs),positioned between the A- and D-elements. A tip of the BB′ palindromecontains RBE′, a cis-acting element essential for optimal Rep-specificactivity. During replication, the terminus folds on itself and serves asa primer to initiate a leading-strand synthesis. At the elongation step,the complementary strand is displaced and may serve as an independentsecond replication template. The result of this first round of DNAsynthesis is a linear duplex replication form monomer (Rfm) with acovalently closed hairpin on one end. Rep-mediated nicking of theoriginal strand then creates a 3′-OH primer and the hairpin is extended.If nicking and subsequent ITR repair do not occur before the secondround of replication is initiated on an opposite newly formed 3′ end,then continued DNA synthesis leads to formation of a replication formdimer (Rfd), which can be organized head-to-head (H-H) or tail-to-tail(T-T), but never head-to-tail. The model also predicts that linearduplex structures are intermediates of packaging. Using these as atemplate, the other two Rep proteins (Rep52 and Rep40) generatesingle-stranded progeny genomes which are then encapsidated intopreformed capsids.

One of the great challenges in effectively applying gene therapy tohuman disease is the development of simple systems for rapidlygenerating high volumes of high titer viruses completely uncontaminatedby potentially toxic helper viruses. One approach has been thedevelopment of techniques for producing “defective” viral vectors devoidof helper viruses. The most popular vectors include adeno-associatedvirus (AAV) and “gutless” adenovirus vectors which contain only the ITRsand a packaging sequence round the trangene. These harbor no viralgenes, are incapable of replication, and helper viruses can becompletely eliminated. Current strategies for producing such vectors,however, rely on techniques which either limit viral titers or which areso labor and resource intensive that they severely limit the clinicaland commercial viability of these promising systems.

In an attempt to overcome this critical problem, new approaches havebeen attempted, though heretofore with limited success. In one suchapproach, a herpes amplicon system was created in which essential AAVgenes (Rep and Cap) were inserted into the amplicon, and a second“helper” herpes simplex virus (HSV) was used to package the amplicon.The mix was then used to package AAV vector. This helper HSV virion wasa mutant HSV that contained a mutation in a gene that is necessary forHSV infection, i.e., the glycoprotein H (gH) (Zhang et al., 1999, Hum.Gen. Ther. 10(15):2527-2537).

U.S. Pat. No. 5,139,941 (Muzyczka et al.) describes a AAV vector havingthe first and last 145 by containing the ITRs, and capable of tranducingforeign DNA into a mammalian cell. U.S. Pat. No. 5,478,745 (Samulski etal.) describes a 165 by fragment containing an AAV 145 by ITR sequencewith the 20 by D sequence found to provide sufficient information in cisfor replication and encapsidation of recombinant DNA fragments intomature AAV virions. U.S. Pat. No. 5,436,146 (Shenk et al.) describehelper free stocks of recombinant AAV vectors. Collaco et al. (1999)Gene 238:397-405 describe a helper virus-free packaging system forrecombinant AAV vectors.

SUMMARY OF THE INVENTION

The present invention provides helper free, fully defective viralvectors produced with high titers. The novel vectors of the inventionare based, in part, on the initial discovery of a minimal 61 by ADsequence required for circular AAV replication. This 61 by sequence (SEQID NO:16) acts as both an origin of circular AAV (cAAV) replication anda packaging signal.

Further studies of cAAV replication revealed that the sequence requiredfor replication is a sequence comprising TGGCCAA (“the loop sequence”)flanked on each side by complementary sequences, such that a hairpinstructure is formed by the complementary sequences hybridizing to eachother. The flanking complementary sequences may be any complementarysequences of any length. In one embodiment, the flanking complementarysequences may be 5-10 by in length. In a preferred embodiment, theflanking sequences are 7 by in length. Further experiments have shownthat a one base mismatch in the complementary flanking sequencesprovides improved replication. Accordingly, in a specific embodiment,the complementary flanking sequences comprise a one base mismatch. In amore specific embodiment, base 5 of a 7 base complementary flankingsequence contains a mismatched base.

According, in a first aspect, the invention features a nucleotidesequence capable of directing circular adeno-associated virusreplication, comprising a loop sequence TGGCCAA flanked on the 5′ and 3′sides by complementary sequences, wherein a hairpin structure is formedbetween the complementary sequences. In one embodiment, thecomplementary flanking sequences are between 5-10 base pairs in length.In a more specific embodiment, the complementary sequences are 7 basepairs in length. In one embodiment, the complementary flanking sequencescomprise a one base mismatch, resulting in improved cAAV replication. Ina more specific embodiment, the complementary sequences are 7 base pairsin length, and the mismatch is at base 5. In one embodiment, thenucleotide sequence capable of directing circular adeno-associated virusreplication is about 61 by in total length. In a more specificembodiment, the nucleotide sequence is SEQ ID NO:16.

In a second related aspect, the invention features a helper-free fullydefective cAAV vector comprising the (i) at least one of the nucleotidesequence of SEQ ID NO:16, and (ii) a heterologous nucleic acid sequenceencoding a protein of interest. In more specific embodiment, the vectorof the invention comprises two of the nucleotide sequence having thesequence of SEQ ID NO:16.

The cAAV vector of the invention possesses several important featuresnot found in prior art vectors. For example, in one embodiment, the cAAVvector of the invention preferably retains one 61 by AAV sequence,providing increased capacity for insertion of foreign DNA by eliminatingan additional 230 by of viral sequences relative to prior art vectors.In another embodiment, the cAAV vector retains two 61 by AAV sequences.Further, as shown in the Examples below, this vector is capable of beingpackaged such that it is suitable for use in gene therapy applications.Still further, the cAAV vector of the invention provides improved shortterm expression of a gene of interest and thus provides an importantadvantage for use in treatment of acute conditions requiring rapidexpression of a therapeutic gene of interest.

In more specific embodiments, the defective cAAV vector of the inventioncomprises a nucleic acid sequence encoding a protein of interestoperably linked to a promoter sequence. In more specific embodiments,the promoter is an inducible promoter. In even more specificembodiments, the inducible promoter is selected from the groupconsisting of a metallothionein promoter, a tetracycline promoter, or aheat shock protein promoter.

In another embodiment, the cAAV vector of the invention comprises anucleic acid sequence encoding a therapeutic protein of interest. Inmore specific embodiments, the therapeutic protein of interest isselected from the group consisting of a a hormone, e.g., insulin; anenzyme, such as tyrosine hydroxylase, adenosine deaminase, phenylalaninehydroxylase; or a growth factor, e.g., glial-derived neurotrophic factor(GDNF), nerve growth factor (NGF).

In a third aspect, the invention features a method of treating an acutemedical condition in a subject in need thereof, comprising administeringa circular adeno-associated virus (cAAV)-derived vector comprising atleast one 61 by element comprising the sequence of SEQ ID NO:16, and anucleic acid sequence encoding a therapeutic protein of interestoperably linked to a promoter sequence, wherein the therapeutic proteinis expressed within 1 day after administration of the cAAV-derivedvector.

In other embodiments, expression is achieved within 8-24 hours afteradministration; preferably within 8-12 hours. In a further embodiment,expression is achieved within 24 hours and expression is increased 10fold within 48 hours.

In a fourth aspect, the present invention provides methods for preparinghelper free, fully defective cAAV and traditional AAV vectors that canbe produced with high titers. In one embodiment of this method, areplication-defective helper viral vector is employed that comprises (i)at least one heterologous nucleic acid which is necessary but notsufficient for the replication and packaging of a defective viralvector, and (ii) requires the expression and/or transcription of atleast one exogenous nucleic acid to replicate (and/or to be packaged).The replication-defective helper viral vector and the defective viralvector are placed into a permissive cell that contains the exogenousnucleic acid(s) required to replicate and preferably package thereplication defective helper viral vector and any remaining genesrequired to replicate and preferably package the defective viral vector.Thus, in the permissive cell, the replication-defective helper viralvector is replicated and preferably packaged and the defective viralvector is replicated and packaged. The resulting mixture ofreplication-defective helper viral vector and defective viral vector istermed the production stock.

In a fifth aspect, the present invention provides for a method ofpropagating cAAV-derived vectors and growing to high titer. In oneembodiment of this method, the initial cAAV-derived stock is used toco-infect fresh cells with a helper adenovirus. The resulting mixedstock is then used to re-infect fresh cells, and this is then repeatedlyre-used as necessary. The cAAV-derived vectors are then purified andseparated from the adenovirus by column purification. In anotherembodiment of this method, the helper adenovirus is replaced by helperherpes simplex virus. In a preferred embodiment, the initialcAAV-derived stock is used to infect cells expressing the adenovirusE1a, E2a, E4, VA RNA gene products and the AAV rep and cap gene products(“necessary adenovirus and AAV gene products”). The resulting stock canbe used to re-infect fresh cells expressing these gene products, andthis is then repeatedly re-used as necessary. No helper virus isproduced by this method, so the cAAV-derived vectors generated by thismethod are simply purified from cellular debris. In another embodimentof this method, the cells used are 293 cells, which endogenously expressthe adenovirus E1a gene product. In another embodiment of this method,the necessary adenovirus and AAV gene products are provided by a plasmidwhich is transfected into cells prior to infection with the cAAV-derivedstock. In another embodiment of this method, a cell-line is used whichendogenously expresses the adenovirus and AAV gene products necessaryfor cAAV-derived vector propagation.

The production stock of replication-defective helper viral vector(packaged or not) and packaged defective viral vector can be amplifiedby co-infecting another permissive cell. This amplification can berepeated until a desired titer is obtained. When a desired titer isachieved, the production stock of replication-defective helper viralvector and packaged defective viral vector is placed into anon-permissive cell which comprises the heterologous nucleic acid(s)required to replicate and package the defective viral vector inconjunction with the heterologous nucleic acid of the defective helperviral vector, but is missing the exogenous nucleic acid(s) required toreplicate the replication defective helper viral vector.

In a sixth aspect, the invention features a defective helper vector foruse in the production of a packaged defective viral vector. A defectivehelper vector of the present invention requires the expression and/ortranscription of one or more exogenous nucleic acid(s) to replicateand/or be packaged and preferably comprises one or more heterologousnucleic acid(s) that aids in the replication and/or packaging of adefective viral vector.

In one embodiment, the defective helper vector is a modified virus. Inmore specific embodiments, the modified virus is a cytomegalovirus(CMV), an adenovirus (Ad), a simian vacuolating virus 40 (SV40), a humanpapillomavirus (HPV), a Hepatitis B virus, a JC papovaviridae virus, anEsptein Bar Virus (EBV), or a herpes simplex virus (HSV). In a morespecific embodiment, the defective helper vector is a modified HSV thatlacks both copies of its ICP4 gene, and comprises the adenoviral genesE1A, E2a, E4orf6, and VAI RNA. In another specific embodiment, thedefective helper vector comprises E1A, E2a, E4orf6, and VAII RNA inplace of VAI RNA. In another specific embodiment, the defective helpervector comprises E1A, E2a, E4orf6, and both VAI RNA and VAII RNA.Preferably the defective helper vector further comprises the adenoviralgene E1B.

In a seventh aspect, the present invention features a compositioncomprising a defective helper vector of the present invention combinedwith a defective viral vector. In one embodiment, this composition is aproduction stock of defective helper vector and packaged defective viralvector. In another embodiment the composition is a production stock ofpackaged defective helper vector and packaged defective viral vector. Ina more specific embodiment, the defective viral vector is the circularadeno-associated virus (cAAV)-derived vector described above and in thefollowing Examples.

In an eighth aspect, the invention provides mammalian cells thatcomprise a plasmid encoding the AAV genes Rep and Cap. Preferably theplasmid has an Epstein-Barr Viral origin of replication. In analternative embodiment, the mammalian cell further encodes the HSV geneICP4. In a specific embodiment, the mammalian cell encodes Cap, E4orf6and E2a under the control of inducible promoters that are inducible by afirst inducer and Rep under the control of an inducible promoterinducible by a second inducer, wherein the mammalian cell also expressesboth VAI RNA and E1A. In one embodiment, the mammalian cell furtherexpresses E1B. In another embodiment, the inducible promoters that areinducible by a first inducer are tet-responsive promoters. In yetanother embodiment, the inducible promoter inducible by a second induceris a metallothionein promoter.

In a ninth aspect, the invention provides methods for generating aproduction stock of packaged defective viral vectors and defectivehelper vectors. Preferably the production stock comprises of packageddefective viral vectors and packaged defective helper vectors. One suchmethod comprises placing a defective helper vector and a defective viralvector into a permissive cell and thereby allowing the defective viralvector and the defective helper vector to be replicated and at least thedefective viral vector be packaged. Preferably the dhlpv comprises (i)one or more helper heterologous nucleic acid(s), the expression and/ortranscription of which are necessary but not sufficient for thereplication or packaging of the defective viral vector in the permissivecell, but (ii) further requires the expression and/or transcription ofone or more exogenous nucleic acid(s) to replicate and be packaged. Thepermissive cell preferably comprises (i) the exogenous nucleic acid(s)required to replicate and package the dhlpv, and (ii) further comprisesone or more ancillary heterologous nucleic acids, the expression and/ortranscription of which in conjunction with the expression and/ortranscription of the helper heterologous nucleic acid(s) enables thereplication and/or packaging of the defective viral vector in thepermissive cell thereby allowing a production stock of packaged dhlpvand dvv to be generated.

In a particular embodiment of this type, the dvv further comprises aheterologous nucleic acid of interest. In a preferred embodiment of thistype, the dvv is a defective AAV vector. In another embodiment the dvvis a gutless adenoviral vector. A production stock generated by a methodof the present invention is also part of the present invention.

A production stock of the present invention obtained by any of themethods of the present invention can be further amplified by placing(e.g., co-infecting) the defective helper vector and the packageddefective viral vector of the production stock into a fresh permissivecell. This process can may be repeated as desired to furtherincrease/optimize the titer.

In a tenth aspect, the invention provides kits for preparing aproduction stock of packaged defective viral vectors (dvv) and defectivehelper vectors (dhlpv). In one embodiment, the kit comprises a defectivehelper vector of the present invention and a packaged defective viralvector. A preferred embodiment includes a permissive cell thatcomprises: (i) one or more exogenous nucleic acid(s) required toreplicate (and preferably) package the dhlpv, and (ii) one or moreancillary heterologous nucleic acids, the expression and/ortranscription of which in conjunction with the expression and/ortranscription of the helper heterologous nucleic acid(s) enables thereplication and packaging of the defective viral vector in thepermissive cell. In a more specific embodiment, the kit furthercomprises a non-permissive cell that (i) does not comprise one or moreexogenous nucleic acid(s) required to replicate the dhlpv, but doescomprise (ii) one or more ancillary heterologous nucleic acids, theexpression and/or transcription of which in conjunction with theexpression and/or transcription of the helper heterologous nucleicacid(s) enables the replication and packaging of the defective viralvector in the non-permissive cell. Preferably a kit of the presentinvention further comprises a protocol for producing the helper freedefective viral vectors.

In an eleventh aspect, the invention features a packaging system forgenerating a helper-free defective viral vector. One such methodcomprises placing (e.g., co-infecting) a production stock of defectivehelper vector and packaged defective viral vector into a non-permissivecell that comprises one or more ancillary heterologous nucleic acids,the expression and/or transcription of which in conjunction with theexpression and/or transcription of the helper heterologous nucleicacid(s) enables the replication and/or packaging of the defective viralvector in the non-permissive cell. However, the replication and/orpackaging of the dhlpv is prevented because the non-permissive cell doesnot comprise the exogenous nucleic acid(s) required. Thus, a helper-freedefective viral vector is obtained.

In a twelfth aspect, the invention further provides methods ofdelivering a gene of interest to a target tissue of an animal subjectusing a helper-free defective viral vector of the present invention. Onesuch method comprises administering the vector directly to the tissue ofthe animal subject. In addition, the present invention provides anon-human mammalian host transformed with a helper-free defective viralvector of the present invention. Such non-human mammalian hosts can beused as animal model for treatment and/or curing of a condition ordisease.

Useful in the method of the invention are the use of recombinationsequences recognized by a recombinase enzyme. Such methods are describedin, for example, U.S. Pat. No. 6,350,575 (Lusky et al.), whichpublication is herein specifically incorporated by reference in itsentirety.

Other objects and advantages will become apparent from a review of theensuing detailed description taken in conjunction with the followingillustrative drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the sequences for pTRT (SEQ ID NO:13), pBB′AD (SEQ IDNO:14), pBB′Atrs (SEQ ID NO:15), pAD (SEQ ID NO:16), pAtrs (SEQ IDNO:17), pDtrs (SEQ ID NO:18), and a pAD mutant (SEQ ID NO:19).

FIGS. 2-4. Southern blot analysis of replication of cAAV genomescontaining deletions in ITRs. FIG. 2: Restriction maps of predictedreplicative intermediates: a linear monomer (Rfm), circular monomer(cAAV), head-to-head dimer (Rfd, H-H), and tail-to-tail dimer (Rfd,T-T). ITRs are represented by arrows, while the TRT domain is shown as ablack box. Vertical lines indicate positions of XbaI sites. The sizes ofthe fragments liberated following XbaI cleavage and recognized by theCMV promoter-specific probe (dotted line) are shown next tocorresponding structures. The position of a 1.2-kb fragment released byDpnI from input plasmids is also indicated. FIG. 3: Replication ofconstructs shown in FIG. 1 following co-transfection withpAd.Help.Rep.Cap.zeo into 293 cells. Hirt DNA was extracted 72-hpost-transfection and 5% of the total yield from a 35-mm culture wellwas digested with DpnI alone or DpnI and XbaI. Samples were resolved ona 0.9% agarose gel and the blots were hybridized with a ³²P-labeled CMVpromoter probe. The relative migration of 1-kb size markers is shown tothe left of the blot. The AAV replicative intermediates as well as theinput plasmid are indicated along the right side of the blot. FIG. 4:replication of the same cAAV constructs after co-trasfection withpRep.Cap into adenovirus-infected 293 cells. Cells were harvested 48-hpost-transfection and samples were analyzed as described for blot (FIG.3).

FIG. 5-6. Comparison of replication of pCis and pAD. FIG. 5: Schematicrepresentation of pCis and pAD. Positions of XbaI sites are indicated.ITRs of pCis are drawn as arrows and the AD domain of pAD is denoted asa box. XbaI cleavage of DpnI-resistant circular species followed byhybridization with a CMV promoter-specific probe (dotted line) isexpected to produce 2.5-kb and 3.2-kb bands for pCis and pAD,respectively. cAAVs assembled during pCis replication are similar insize and structure to pAD except that they contain the TRT domain. SincepCis would generate the TRT domain that is slightly larger than the ADdomain, cAAVs derived from pCis would produce a band of 3.5 kb insteadof 3.2 kb. FIG. 6: pCis and pAD were assayed for replication asdescribed in the legend of FIG. 3. Note that linear forms are present inpCis replication, but they are absent in pAD replication. The relativemigration of 1-kb size markers is shown to the left of the blot.Replicative intermediates are the same shown in FIG. 1 and are labeledalong the right side of the blot.

FIG. 7. Site-specific integration of AAV.AD. 293 cells were infectedwith AAV.AD or AAV.TRT (positive control) in the presence or absence ofRep. Genomic DNA was extracted 72-h post-infection and subjected tonested PCR. Mock-infected cells were included as a negative control. PCRproducts were analyzed on an ethidium bromide gel (top) and duplicatesouthern blots (bottom), which were analyzed using ³²P-labeledITR-specific or AAVS1-specific probes. A 100-bp ladder was loaded intothe first lane. Viruses used for the assay are indicated along the topof the gel. The AAV genome, AAVS1 integration site, position of primersand probes are schematically represented at bottom.

Comparison of pP5 and pAD replication. pP5 and pAD were assayed forreplication as described in the legend of FIG. 3. pC was included as anegative control. Note the absence of linear duplex intermediates inlanes 1 and 2. Replicating cAAV and input plasmids are indicated. 1-kbsize markers are shown to the left of the blot.

DETAILED DESCRIPTION

Before the present methods and treatment methodology are described, itis to be understood that this invention is not limited to particularmethods, and experimental conditions described, as such methods andconditions may vary. It is also to be understood that the terminologyused herein is for the purpose of describing particular embodimentsonly, and is not intended to be limiting, since the scope of the presentinvention will be limited only the appended claims.

As used in this specification and the appended claims, the singularforms “a”, “an”, and “the” include plural references unless the contextclearly dictates otherwise. Thus for example, references to “the method”includes one or more methods, and/or steps of the type described hereinand/or which will become apparent to those persons skilled in the artupon reading this disclosure and so forth.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can be used inthe practice or testing of the present invention, the preferred methodsand materials are now described. All publications mentioned herein areincorporated herein by reference to disclose and described the methodsand/or materials in connection with which the publications are cited.

DEFINITIONS

The term “gene” refers to an assembly of nucleotides that encodes apolypeptide. A gene, as used in the present invention, includes bothcDNA and genomic DNA nucleic acids and therefore, does not necessarilycorrespond to the naturally occurring gene which contains all of theintrons and regulatory sequences, present in the natural genomic DNA; agene can merely contain a coding sequence for a particular protein.

A “vector” as used herein is a genetic construct that facilitates theefficient transfer of a nucleic acid (e.g., a gene) to a cell. The useof a vector can also facilitate the transcription and/or expression ofthat nucleic acid in that cell. Examples of vectors include plasmids,phages, amplicons, viruses and cosmids, to which another DNA segment maybe attached so as to bring about the replication of the attachedsegment.

A “viral particle” is a vector that has been packaged in viral proteins,i.e., a viral coat.

A vector is “packaged” when it is placed into a viral coat as part of avirus or viral particle.

As used herein, a “heterologous nucleic acid” is a nucleic acid that hasbeen placed into a vector or cell that does not naturally comprise thatnucleic acid. In one embodiment, a heterologous nucleic acid encodes aprotein, i.e., a “heterologous gene” and but can also comprise aregulatory sequence without a coding sequence (e.g., a specificpromoter), an antisense nucleic acid, a ribozyme, a tRNA or othernucleic acid.

As used herein a “helper heterologous nucleic acid” is a heterologousnucleic acid comprised by a helper vector. An “ancillary heterologousnucleic acid” is a heterologous nucleic acid that is not comprised bythe helper vector. This denotation is made solely to distinguish thelocation of a particular heterologous nucleic acid.

As “heterologous or foreign nucleic acid of interest” is a heterologousnucleic acid that has been placed into a defective viral vector forreasons other than to promote viral replication and/or viral packaging.In one embodiment, the heterologous nucleic acid has been placed into adefective viral vector for an ultimate therapeutic use in a gene therapyprotocol, and/or as a marker. In a particular embodiment, theheterologous nucleic acid of interest encodes a protein.

A nucleic acid is “exogenous” to a vector when the nucleic acid is notcomprised by the vector. The gene product of the vector can then besupplied by either a second vector and/or a permissive host cell whichcontains the exogenous nucleic acid. As exemplified below, an exogenousnucleic acid is contained by the permissive cell and is required for thereplication and/or packaging of the defective helper viral vector.

A “defective viral vector”, abbreviated “dvv” is a viral vector thatrequires the expression and/or transcription of at least one nucleicacid that it lacks in order to be replicated and/or packaged. In oneembodiment, the dvv is a replication defective viral vector. In a morespecific embodiment, a defective viral vector also comprises aheterologous nucleic acid of interest. More specifically, a defectiveviral vector comprises a minimum number of viral genes, and morepreferably does not encode a viral protein.

The term “defective helper vector”, abbreviated as “dhlpv” is usedinterchangeably with the term “replication defective helper vector” andis a vector that requires the expression and/or transcription of atleast one nucleic acid that it lacks in order to be replicated. A dhlpvalso encodes at least one nucleic acid that when expressed and/ortranscribed in a cell can aid in the replication or packaging of adefective viral vector. In the examples below, the dhlpv comprisesheterologous nucleic acids that aid in the replication or packaging of adefective viral vector.

As used herein, a “permissive cell line” is a cell line (or cell) inwhich a replication defective helper vector can replicate, and adefective viral vector can be replicated and packaged. A “non-permissivecell line” is a cell line (or cell) in which the replication defectivehelper vector contained in a mixture of a defective helper vector and adefective viral vector cannot replicate but the defective viral vectorcan be replicated and packaged. Therefore, whereas a defective viralvector can be replicated and packaged in its correspondingnon-permissive cell line, the non-permissive cell line does not supportthe replication of the corresponding defective helper vector, asexemplified below.

“Production stock” is a composition comprising a defective helper vector(preferably packaged) and a packaged defective viral vector. Aproduction stock can be used to generate additional packaged defectiveviral vector and defective helper virus when placed into a permissivecell. In can also be used to generate helper free packaged defectiveviral vector when placed into a non-permissive cell. In a particularembodiment, the production stock is comprised of a packaged defectivehelper virus and a packaged defective viral vector.

Transcriptional and translational control sequences are DNA regulatorysequences, such as promoters, enhancers, polyadenylation signals,terminators, and the like, that provide for the expression of a codingsequence in a host cell.

A “promoter sequence” is a DNA regulatory region capable of binding RNApolymerase in a cell and initiating transcription of a downstream (3′direction) coding sequence. For purposes of defining the presentinvention, the promoter sequence is bounded at its 3′ terminus by thetranscription initiation site and extends upstream (5′ direction) toinclude the minimum number of bases or elements necessary to initiatetranscription at levels detectable above background. Within the promotersequence will be found a transcription initiation site (convenientlydefined by mapping with nuclease S1), as well as protein binding domains(consensus sequences) responsible for the binding of RNA polymerase.Eukaryotic promoters will often, but not always, contain “TATA” boxesand “CAT” boxes. Prokaryotic promoters contain Shine-Dalgarno sequencesin addition to the −10 and −35 consensus sequences.

An “expression control sequence” is a DNA sequence that controls andregulates the transcription and translation of another DNA sequence. Acoding sequence is “operatively under the control” of transcriptionaland translational control sequences in a cell when RNA polymerasetranscribes the coding sequence into a precursor RNA, which is thentrans-RNA spliced to yield mRNA and translated into the protein encodedby the coding sequence.

A nucleotide sequence is “operatively under the control” of a geneticregulatory sequence when the genetic regulatory sequence controls and/orregulates the transcription of that nucleotide sequence. That geneticregulatory sequence can also be referred to as being “operativelylinked” to that nucleotide sequence.

A “genetic regulatory sequence” is a nucleic acid that: (a) acts in cisto control and/or regulate the transcription of a nucleotide sequence,and (b) can be acted upon in trans by a regulatory stimulus to promoteand/or inhibit the expression of the nucleotide sequence. Therefore, aninducible promoter is a genetic regulatory sequence. In addition, aportion of a promoter (e.g., fragment/element) that retains and/orpossesses the ability to control and/or regulate the expression of anucleotide sequence either alone or in conjunction with an alternativepromoter or fragment thereof (e.g., a chimeric promoter) is also agenetic regulatory sequence. Such fragments include, response elements(genetic response elements) and promoter elements.

A “signal sequence” can be included before the coding sequence. Thissequence encodes a signal peptide, N-terminal to the polypeptide, thatcommunicates to the host cell to direct the polypeptide to the cellsurface or secrete the polypeptide into the media, and this signalpeptide is clipped off by the host cell before the protein leaves thecell. Signal sequences can be found associated with a variety ofproteins native to prokaryotes and eukaryotes.

A DNA sequence is “operatively linked” to an expression control sequencewhen the expression control sequence controls and regulates thetranscription and translation of that DNA sequence. The term“operatively linked” includes having an appropriate start signal (e.g.,ATG) in front of the DNA sequence to be expressed and maintaining thecorrect reading frame to permit expression of the DNA sequence under thecontrol of the expression control sequence and production of the desiredproduct encoded by the DNA sequence. If a nucleic acid that one desiresto insert into a recombinant DNA molecule does not contain anappropriate start signal, such a start signal can be inserted in frontof the gene.

“Treatment” refers to the administration of medicine or the performanceof medical procedures with respect to a patient, for either prophylaxis(prevention) or to cure the infirmity or malady in the instance wherethe patient is afflicted.

General Description

The present invention provides a facile method for producing high titer,helper free, fully defective viral vectors. This method can be fullyautomated using a “mixed virus” system and multiple cell lines whichpermits ready amplification and renewal of the vector stock, while alsopermitting production of large volumes of pure, high titer vectors. Theinvention also provides methods of using the high titer, helper free,fully defective viral vectors suitable for use as a method of treatmentin a gene therapy protocol.

The studies below demonstrate that a 61 by AD sequence (SEQ ID NO:1)functions as both an original of circular AAV replication and apackaging signal. The identified cis-acting replication elementencompasses the A-stem and the D-sequence with an intact trs andapparently does not require any other ITR domains. A vector comprisingthe 61 by AD sequence is particularly useful for treatment of acutemedical conditions where rapid expression of a therapeutic gene, e.g.,within 8-12 hours or 1-2 days, is required to achieve improvement or toprevent damage to a subject suffering the acute medical condition. Acutemedical conditions that would benefit from early expression of atherapeutic agent include neurodegenerative diseases (such asParkinson's disease), strokes, cardiovascular episodes, and some typesof tumors. The vector of the invention comprising the 61 by AD sequenceis also useful in gene therapy requiring long term expression.

The present invention employs a defective helper vector that isconstructed to be capable of replication only in a permissive cell line.The defective helper vector is preferably constructed so as to compriseheterologous nucleic acids from at least one other virus. This ensuresthat the defective helper vector cannot undergo homologous recombinationand revert to a harmful wild type form. It also more readily permits theremoval of the defective helper vector when the defective helper vectorhas a viral coat that differs from that of the defective viral vectors.In any case, the heterologous nucleic acids of the defective helpervector supply at least some helper functions for at least one otherviral system. Preferably the defective helper vector is constructed tosupply some but not necessarily all helper functions for at least oneother viral system.

In one embodiment, the permissive cell line further contains theremaining helper functions which, in conjunction with the helperheterologous nucleic acids, permit the packaging of a replicationdefective viral vector. The resulting packaged replication defectiveviral vector can be used as a gene transfer vehicle in gene therapy, tohelp generate transgenic non-human animals, and can be used to transformmammalian cells in culture.

In a particular aspect of the present invention, a replication defectiveviral vector comprising a nucleic acid of interest requires both areplication defective helper vector and the remaining helper functionssupplied by the permissive cell (or an amplicon or plasmid contained bythe cell) to be successfully packaged. Similarly, to replicate, thedefective helper vector requires the expression of one or moreheterologous genes contained by the permissive cell. Therefore, when thereplication defective viral vector and the replication defective helpervector are placed into the permissive cell, they are both replicated andat least the replication defective viral vector is packaged. Thereplication defective helper vector and packaged replication defectiveviral vector together form a “production stock” that can be re-infectedinto fresh permissive cells to continuously produce additionalreplication defective helper vector and packaged replication defectiveviral vector.

In one embodiment, the replication defective viral vector can bepurified away from the defective helper vector by placing the“production stock” in a non-permissive cell line that can provide therequisite helper functions in conjunction with the replication defectivehelper vector to replicate and package the replication defective viralvector, but does not support the replication of the replicationdefective helper vector. In the non-permissive cell the replicationdefective helper vector can still aid in the production of the packageddefective viral vector, but no new replication defective helper vectorcan be produced. The resulting stock, called the “vector stock”, is purereplication defective viral vector completely free of helper viruses.The genes required to package the replication defective viral vectorcontained by the replication defective helper vector is preferably in apackaged virus particle. Alternatively, however, it can also be insertedin a vector plasmid and/or helper virus mix and this plasmid and/or mixmay be used in lieu of and/or in conjunction with a replicationdefective helper virus.

Two examples described below demonstrate the ability of the presentinvention to produce high titers of defective viral vectors free ofhelper virus. The defective helper vector can be derived from HSV,cytomegalovirus, adenovirus, SV40, human papillomavirus, Hepatitis Bvirus, JC virus, or EBV. The defective helper vectors contain one ormore deletions in an essential gene which prevents its reproduction. Thedefective helper vector can also contain one or more helper sequencesfrom the wild-type virus from which the defective viral vector isderived and/or from a third virus that encodes suitable helper genes.Preferably, the replication defective helper vector is a viral particle.Additional helper sequences also may be inserted into a defectiveamplicon or plasmid derived from the helper virus which can be packagedalong with a replication defective helper viral particle to serve as amixed helper stock. Additional necessary helper functions may beinserted into a cell line for vector production, although this is notessential.

Vector stocks of the present invention can be produced in large scalequantities. Any defective DNA viral vector can be amplified by firstbeing introduced into a production (i.e., permissive) cell line thatexpresses the key missing gene(s) necessary for reproduction of thedefective helper vector and in conjunction with the defective helpervector expresses the key gene(s) necessary for reproduction and/orpackaging of the defective viral vector. This results in a mix ofpackaged defective viral vector and defective helper vector. Thisproduction stock can then be used to re-infect larger amounts of freshproduction cells, resulting in increasing amounts of packaged defectiveviral vector and defective helper vector. Defective viral vector canthen be purified by infecting the mix into non-permissive cells which donot contain the essential gene(s) required for the defective helpervector to replicate. This prevents reproduction of the defective viralvector, but still supports reproduction of the defective viral vector,resulting in a pure stock of defective viral vectors. Preferably thedefective viral vector contains only recognition signals for replicationand packaging but no viral genes.

The methodology disclosed herein therefore permits rapid packaging ofany vector plasmid without the need to create new cell lines. Theresulting replication defective viral vector is free of contaminatinghelper viruses, including “non-functional” viral particles. Furthermore,the production stock can be easily grown and amplified through repeatedrounds of re-infection in permissive cells without the need to transfectnew cells or add any new helper vectors/viruses. Since this isessentially a single-step process, it can be applied to automated,bioreactor settings to permit commercial-scale large volumes of“production stock”. Furthermore, pure defective viral vectors can beobtained at any time by simply infecting the correspondingnon-permissive cell line with the production stock.

In addition to ease of use and efficient, high volume, high titerproduction, the methodology provided by the present invention has theadvantage of permitting the storage of high volumes of a single lot ofproduction stock which can be readily converted to a gene therapyvehicle by the “purification” infection of the non-permissive cell line.Therefore, the present invention creates an unprecedented opportunityfor quality control and lot analysis, which is essential for reliableclinical and commercial applications.

Production of Helper-Free Defective Viral Vectors

An antibiotic-sensitive cell line (such as hygromycin as exemplifiedbelow, neomycin, ampicillin, penicillin, tetracycline and the like) canbe obtained and/or constructed to express a nucleic acid to produce agene product that is required for the replication and/or packaging of agiven replication-defective helper vector. This nucleic acid is referredto as an exogenous nucleic acid. The ICP4 gene of HSV is the exogenousnucleic acid described in the Examples below, and is employed along witha replication defective HSV helper vector that lacks the ICP4 gene,because the ICP4 gene product is essential for late HSV gene expressionand for HSV replication.

Cells that can be used to generate permissive and non-permissive celllines include A549, WEHI, 3T3,10T½, BHK, MDCK, COS 1, COS 7, BSC 1, BSC40, BMT 10, VERO, WI38, HeLa, 293, Saos, C2C12, L Cells, HT1080, HepG2,and primary fibroblasts, hepatocytes, or myoblasts. Cell lines thatexpress Rep and Cap also have been described previously (see U.S. Pat.No. 5,658,785).

A corresponding antibiotic resistant plasmid can be constructed so as tocontain one or more heterologous nucleic acids that are required for thereplication and/or packaging of the replication-defective viral vector.When the heterologous nucleic acid(s) are used in conjunction with oneor more heterologous nucleic acid contained by a defective helpervector, the heterologous nucleic acid(s) of the plasmid are referredherein to as ancillary heterologous nucleic acids, and the heterologousnucleic acid(s) contained by the defective helper vector can be referredto as helper heterologous nucleic acid(s).

In Example 1 below, the defective viral vector is derived from an AAVvirus so two essential AAV genes, Rep and Cap were inserted into theplasmid and are the ancillary heterologous nucleic acids. In Example 2below, the defective viral vector is a “gultless” adenoviral vector sothe ancillary heterologous nucleic acids of the plasmid were a subset ofthe adenovirus genome containing the adenovirus genome including theessential adenoviral fiber protein, but the E1A, E1B, E2a, E4orf6, andVAI RNA sequences were deleted. When the defective helper vector and thepermissive cell have heterologous nucleic acids from the same viralgenome, it is preferred that no sequence overlap is maintained betweenthe heterologous nucleic acids included in the plasmid and thoseincluded in the defective helper vector to prevent any chance ofhomologous recombination between the two.

In a more specific embodiment, the plasmid also contains theEpstein-Barr Virus (EBV) origin of replication and the EBNA gene. Whenthis plasmid is introduced into this cell line, the Epstein-Barr Virus(EBV) origin of replication and the EBNA gene product permit continuousmaintenance of the plasmid in an episomal state. Alternatively, theplasmid may be generated to have a particular drug resistance and thencan be inserted into the cell and maintained using standard drugselection methodology (e.g., the plasmid bestows the particular drugresistance to the cell and the cells are grown in the presence of thedrug).

Selection based upon antibiotic resistance allows a cell line containingthe plasmid which expresses the ancillary heterologous nucleic acid(s)of the plasmid and the exogenous nucleic acid(s) of the cell. This cellline is referred to herein as the permissive cell since both thedefective viral vector and the defective helper vector can be replicatedand at least the defective viral vector can be packaged in thepermissive cell line. A non-permissive cell line is also prepared thatis analogous to the permissive cell line except the non-permissive cellline does not express the exogenous nucleic acid(s) required for thereplication of the defective helper vector. As is apparent, theantibiotic resistance is only employed to allow the selection of thecells that contain the plasmid. Alternative methods of identificationand isolation of cells containing the plasmid can be performed. One suchmethod uses a plasmid encoding a marker protein (such as greenfluorescent protein). Another uses an antigen marker expressed by theplasmid, along with an fluorescent antibody. In either case, the desiredcells can be isolated by fluorescent cell sorting, for example.

In the Examples below, the ancillary heterologous nucleic acids(Rep/Cap) are expressed at low levels in the absence of defective helpervector, so they are stable within the cell prior to infection. In analternative embodiment, the ancillary heterologous nucleic acid(s) canbe under the control of an inducible promoter. Inducible promotersinclude the metallothionein promoter (e.g., the zinc-inducible sheepmetallothionine promoter), the tetracycline-on and the tetracycline-offpromoters (Gossen et al. (1992) Proc. Natl. Acad. Sci., 89:5547-5551;Gossen et al. (1995) Science 268:1766-1769; Harvey et al. (1998) Curr.Opin. Chem. Biol., 2:512-518) and the heat shock protein 70 promoter.Therefore, in a particular embodiment, a cell that contains theancillary heterologous nucleic acid(s) (e.g., in a plasmid) under thecontrol of an inducible promoter are treated with an agent that inducestheir expression prior to placing the defective viral vector and thedefective helper virus into the cell.

A defective helper vector can be prepared by deleting one or more genesthat are required for viral propagation, such as genes that are requiredfor replication and/or packaging. In the Examples below, an HSV virushaving a deletion in both copies of the ICP4 gene was used. A cassettecontaining what will be the helper heterologous nucleic acids can thenbe inserted into the defective helper vector. As disclosed below, the 5adenovirus (Ad) genes: E1A, E1B, E2a, E4orf6, and VAI RNA were insertedinto the HSV helper vector missing the ICP4 gene. The resulting hybriddefective helper virus (e.g., the HSV/Ad helper vector described below)can be replicated (and where appropriate packaged) when re-infected intopermissive cells which express the exogenous gene product.

The permissive cells are also co-infected with the ultimate product, adefective viral vector. A defective AAV vector and a “gutless”adenoviral vector are exemplified below. This gutless adenoviral vectorcontained adenovirus termini (harboring origins of DNA replication) anda packaging signal, but no other adenovirus genes. Other suitabledefective viral vectors include but are not limited to cytomegalovirus(CMV), simian vacuolating virus 40 (SV40), human papillomavirus (HPV),Hepatitis B virus, JC papovaviridae virus and Esptein Bar Virus (EBV).

After the co-infection a mixed production stock of packaged defectiveviral vector and defective helper vector is produced. This productionstock can be repeatedly re-infected into fresh permissive cells, readilyyielding increasingly larger quantities of the mixed production stock.When the titer is optimized to a desired value, packaged defective viralvector free of defective helper vector can be produced by passing theproduction stock through the non-permissive cells.

The helper-free defective viral vectors are then isolated from thenon-permissive cells. Any of a number of methods can be used. Forexample, the cells can be subjected to sonication and/or to freeze-thawprotocols. The cell debris then can be removed by centrifugation forexample. Additional purification of the helper-free defective viralvectors from cell debris and cellular components can be performed suchas through the use of an affinity column (e.g., using an antibodyspecific for a coat protein), size exclusion columns, including spincolumns, size exclusion membranes with dialysis, ammonium sulfatefractionation/precipitation, and cesium chloride gradients.

When sequences from the same virus are employed in the defective helpervirus and the plasmid, e.g., adenoviral vector, it is preferred that alarge insertion of “stuffer” DNA be inserted into the viral (e.g.,adenovirus) sequences of the EBV plasmid of the cell lines. The use ofstuffer DNA in a plasmid prevents the plasmid DNA from being packagedbecause the addition of stuffer DNA to the viral DNA of the plasmidmakes it too large to be packaged. For example, since adenovirus canmaximally package up to 105% of its genome size of 35 kb, an addition ofgreater than about 2 kb prevents the DNA from being packaged into anadenoviral particle. Although production of wild-type adenovirus throughrecombination should be prevented by the preferred absence ofcomplementary sequences between the defective helper vector and the cellline, the insertion of the stuffer sequence adds an additional safetymeasure since any unlikely recombinant would be too large to package.

Preferably the defective helper vector is packaged, i.e., a viralparticle that comprises helper heterologous nucleic acids (e.g., theHSV/Ad helper vector). However, in an alternative embodiment, the helperheterologous nucleic acids can be inserted into a replication defectiveviral amplicon (an HSV/Ad amplicon) and this amplicon can then bepackaged in a permissive cell with the aid of a replication defectivehelper virus, e.g., an ICP4-deleted HSV, into a viral coat (e.g., theHSV viral protein coat) forming a viral particle. In one embodiment ofthis type, the permissive cell does not contain any heterologous nucleicacids besides the exogenous nucleic acid required for the replication ofthe viral amplicon. The resulting mixture of defective viral ampliconand defective helper vector (e.g., HSV/Ad amplicon-defective helpervector) can be placed (e.g., re-infected) into a fresh permissive cellallowing the amplification of the mixture. As is readily apparent, whena mixture of a viral amplicon and defective helper vector is employed,the helper heterologous nucleic acids can be distributed in any of thepossible permutations between the defective helper vector and thedefective viral amplicon. All of such permutations are included by thepresent invention.

In an alternative embodiment the ancillary heterologous nucleic acidsequences contained within the cell line (e.g., via a plasmid asexemplified below) can alternatively be supplied by a second amplicon,which could be packaged as part of the helper mix along with theamplicon harboring the helper heterologous nucleic acid sequences. Inyet another embodiment, the permissive cell line could minimally containa lone viral nucleic acid, i.e., an exogenous nucleic acid required forpackaging the defective helper virus, e.g., the HSV ICP4 as exemplifiedbelow, which would be absent in the corresponding non-permissive cellline. In this case all of the other requisite heterologous nucleic acidscould be inserted into a single amplicon, without any viral packagingsignals or origins of replication, and the amplicon could be packagedinto a “helper” amplicon which could autonomously support packaging of adefective viral vector.

The present invention uniquely enables the large scale production ofvector stocks for any selected defective viral vector. Preferably thedefective viral vector is a defective DNA viral vector that does notencode a viral protein but comprises recognition signals for replicationand packaging mediated by exogenous viral genes. In one embodiment ofthe invention, the defective viral vector is a circular AAV-derivedvector comprising one or more 61 by element(s) having the sequence ofSEQ ID NO:1.

When the vectors of the present invention are employed for gene therapy,the recipient may be in need of gene therapy due to one or moremutations in the regulatory region and/or the coding sequence of one ormore genes. Therefore, DNA delivered to that individual may beconsidered heterologous even though it is identical to a gene native tothat individual's species, provided it differs in the regulatory orcoding region from the cognate gene of the individual to whom it isdelivered, and therefore encodes a different gene product or isexpressed to a different degree and/or in different cells, under atleast some conditions.

cAAVs

In addition to the commonly accepted self-priming strand displacementmodel described above, another AAV replication pathway was recentlyidentified which is characterized by the assembly of circular duplexmonomer genomes (cAAV) (Musatov et al. (2000) Virology 275:411-432).These circular species may constitute as much as 10% of monomer duplexintermediates of both wild-type and recombinant AAV, although onoccasion these structures are barely detectable. The circularizationpoint (so-called the “TRT domain”) of cAAV contains a single copy of theITR flanked by two D-elements (D-A′-B′-B-C′-C-A-D). cAAV can eitherreplicate along the accepted strand-displacement pathway followingresolution of the TRT domain (defined here as a “conventional pathway”)or by a mechanism that preserves the integrity of the circularconformation (“alternative pathway”).

The requirement of cAAV for cis-acting elements for replication, therelationship between the two pathways, and the biological significanceof the circular duplex intermediates were investigated in experimentsdescribed below (Example 5). A series of cAAV plasmids containingvarious deletions in the TRT domain were constructed, and analyzed theeffect of these alterations on AAV replication and packaging in cellculture. These experiments led to a novel discovery regarding theidentity and characterization of a minimal ITR sequence necessary andsufficient to support cAAV replication, e.g., the 61 by AD sequence (SEQID NO:1). Interestingly, a small internal palindrome (BB′) known tocomprise an additional Rep-binding element (RBE′) necessary for optimalRep-ITR interaction (Brister et al. (2000) J. Virol. 74:7762-7771) doesnot contribute to the efficiency of cAAV replication, while the trs isan essential cis-acting element. Furthermore, rAAV harboring only the ADdomain replicate exclusively in a circular form and no linear duplexintermediates are assembled.

The experiments below are the first evidence that the conventional andalternative pathways of AAV replication are indeed independent and canbe completely separated. Further, as shown below, these studies revealedthat cAAV genomes with the AD domain are efficient templates for thepackaging of ssDNA as well.

Example 5 below describes the role of a cis-acting element that directscircular Adeno-associated virus (cAAV) replication and packaging.Replication of cAAV constructs containing various deletions in the TRTdomain were assayed using two different models of rAAV propagation incell culture. Hirt DNA samples digested with DpnI or DpnI and XbaI wereresolved on a neutral agarose gel. These enzymes would unambiguouslydistinguish between different replicative intermediates as well as inputplasmid DNA. DpnI selectively cleaves methylated input plasmid but isinactive against templates that have undergone at least one round ofreplication in mammalian cells. As shown in FIG. 2, digestion ofunreplicated plasmid with DpnI followed by hybridization with a CMVpromoter probe is expected to reveal a band of approximately 1.2 kb.When digested with XbaI, replicative form monomers (Rfm) andtail-to-tail dimers (RFd, T-T) should release 0.9-kb and 0.8-kbfragments for extended and closed ends, respectively, while head-to-headdimers (RFd, H-H) are expected to liberate a 1.5-kb band. Finally,circular AAV structures are predicted to produce a unique 3.3-3.5-kbfragment following XbaI digestion, depending upon the size of the ITRelement. As indicated above, DpnI should not cleave any of thereplicative forms.

Southern blots presented in FIGS. 3 and 4 show that DpnI-digestedsamples for pTRT had a banding profile that is characteristic for AAVlytic replication, including linear duplex Rfm and Rfd (FIG. 3, lane 1).It should be noted, that cAAV species are not always detected duringreplication of pTRT in a helper-free system (FIG. 3, lane 2) but can bereadily recognized when adenovirus is used to provide helper functions(FIG. 4, lane 2) or when a conventional cis-plasmid is used as atemplate. When the CC′ hairpin as well as a second copy of the ADsequence were removed (pBB′.AD), dramatic changes in the replicationprofile were observed. No liner duplex intermediates were clearlydetected (FIGS. 3 and 4, lane 3); instead the plasmid replicatedapparently exclusively in a circular form as evidenced by release of theunique 3.3-kb fragment following XbaI digestion. unique for cAAV wasreleased (FIGS. 3 and 4, lane 4). The absence of intact circular formssamples cleaved with DpnI alone is likely due to cAAV migration inmultiple conformations (e.g. supercoiled and relaxed), which would limitconcentration at any one location in a gel. Equal intensities of the1.2-kb bands liberated by DpnI from input DNA in each lane suggests thatthese findings are not a result of variabilities in transfectionefficiency, sample loading or transfer during blotting.

Experiments investigated whether the D-element was essential for thealternative replication pathway. pBB′.Atrs lacks 18 by of this 20-bpsequence while retains 2 by that complement the trs (FIG. 1). As can beseen in FIGS. 3 and 4, lanes 5 and 6, no DpnI-resistant material wasdetected indicating that the D-element is a critical region in theorigin of cAAV replication. To more precisely localize the minimal 5′end of the ITR sequence, the BB′ hairpin in pAD was removed. This smallinternal palindrome has been shown to comprise a cis-acting element(RBE') essential for origin function of the ITR (Brister et al. (2000)J. Virol. 74:7762-7771). Surprisingly, this alteration did not impaircAAV replication (lane 8). However, deletion of the D-element from thisconstruct (pAtrs) completely abolished replication, an observationconsistent with the previous finding of the importance of this domain(lanes 9 and 10).

The involvement of the A-sequence in this pathway was addressed.Construct pDtrs retains the complete D-element and 4 by of theA-sequence that complement the trs, but lacks the rest of this elementincluding the Rbs (FIG. 1). As shown in FIGS. 3 and 4, lanes 11 and 12,this mutation was deleterious for cAAV replication. Vector pC, whichdoes not contain any AAV sequence, was included as a negative control(lanes 13 and 14). Thus, cis-elements required for replication of cAAVcan be assigned to a single AD domain of the ITR. The experiments alsorevealed that that the “conventional” and “alternative” pathways areindeed independent and can be completely separated.

To determine whether trs is necessary for cAAV replication, two pointmutations were introduced into the trs. Nicking normally occurs betweenthe TT residues in the trs, and these were substituted with two CCresidues (FIG. 1). This alteration is expected to completely blockendonuclease reaction mediated by Rep (Brister et al. (1999) J. Virol.73:9325-36). When assayed for replication in 293 cells, this constructfailed to produce DpnI-resistant species compared to a control pADplasmid. Equal intensities of the 1.2-kb bands released after DpnIcleavage serves as a control for equal transfection efficiency and gelloading in this experiment. Thus, trs is an essential cis-element of thealternative pathway of AAV replication.

The extent of plasmid DNA replication in mammalian cells can be easilyassayed by resistance to DpnI and MboI. DpnI is active only towardstemplates that have both adenosines methylated in the GATC recognitionsequence. In contrast, MboI cleaves the same site only if both strandsare unmethylated. Since such methylation is performed only in dam⁺bacteria but not mammalian cells, sensitivity to DpnI and resistance toMboI indicate that the plasmid has not replicated. Following one roundof DNA synthesis, the template becomes hemimethylated and is DpnI- andMboI-resistant. After the second round of replication, both DNA strandswill be unmethylated, and the plasmid will be DpnI-resistant andMboI-sensitive.

The pAD replication products from the experiment described in FIG. 3were analyzed to determine whether cAAVs undergo more than one round ofDNA synthesis during replication. Hirt DNA samples were digested withXbaI to release a 3.2-kb band unique for cAAV and then with DpnI or DpnIand MboI. All DpnI-resistant species were also MboI-sensitive (resultsnot shown). Indeed, a 3.2-kb band corresponding in mobility toreplicated pAD was completely converted to a 1.2-kb fragment positionedbetween two DpnI/MboI sites. This finding establishes that pADreplication products are the result of more that one round of DNAsynthesis.

cAAV replication using pTRT as a template was found to be less efficientcompared to conventional cis-plasmids, which harbor a rAAV genome withtwo complete ITRs separated by a stuffer sequence. To ensure that thesefindings were not limited to a particular set of constructs, but ratherrelevant to a mechanism of AAV replication in general, a regularcis-plasmid was included as a control. This vector (pCis) contains thesame non-AAV sequence as pAD, and has two intact ITRs derived frompsub201 (33) separated by a 2.3-kb stuffer (FIG. 5). As shown in FIG. 6,cAAVs were assembled far more efficiently during pCis propagation thanduring replication of pTRT (compare FIG. 6, lane 2 and FIG. 3, lane 2).Similar intensities of the 1.2-kb bands released after DpnI cleavage ofinput plasmid serve as a control for equal transfection efficiency andgel loading in this experiment (compare lanes 2 and 3 in FIG. 6).Densitometry analysis of this blot established that cAAV intermediatesconstitute approximately 10% of linear duplex structures (Rfm). Thisobservation confirms previous report that cAAV is reproduciblyidentified during AAV replication (Musatov et al. (2000) Virology 275:411-432). Equally important, this experiment revealed that asubstitution of ITRs with a single AD domain enhances replication ofcAAV (compare lanes 2 and 3) while eliminates generation of linearforms. This effect may be underestimated given the fact that pADcontains only one copy of this element while pCis has two AD copies inopposite orientations. Thus, blocking of the primary replication pathwayleads to an increase in the efficiency of the alternative pathway ofreplication.

To address the issue of size constraints, the replication of two otherconstructs of larger size, 2n (9 kb) and 3n (13.6 kb) was assayed. Theplasmids were transfected into 293 cells in equimolar amounts along witha full complement of helper functions. Hirt DNA samples were digestedwith a single-cutting enzyme, resolved on an agarose gel, and theresulting blots were hybridized with an EGFP-specific probe. Results(not shown) show that replication of 2n was significantly impairedcompared to pAD, and there was no detectable 3n replication. In aseparate experiment, the replication of a plasmid of a smaller size (2.3kb) was found to be even more efficient than that of pAD (data notshown). These findings indicate that though replication of cAAV is notlimited to genomes of wt size, it becomes inefficient as the size of atemplate increases.

During replication of cAAV constructs in our experiments, a restrictionendonuclease-resistant smear was always observed on Southern blots. Thesmear could at least in part be attributed to ssDNA that is known tomigrate abnormally in a neutral agarose gel. This finding prompted theinvestigation of packaging of the cAAV constructs. All of the plasmidshave a size of approximately 4.4-4.6 kb so they could be packagedwithout rescue if such rescue-independent encapsidation is possible.Production of infectious virions was directly assayed on 293 cells bylimiting dilution of crude cell lysates. These lysates were preparedfrom a portion of the same samples that were used for the replicationassay described below. This permits conformation of equal plasmidtransfection efficiencies of the plasmids by Southern blotting andallows us to correlate replication profiles and packaging.

We were surprised to discover relatively high numbers of EGFP-positivecells for some samples 24 h post-infection (Table 3). There was a directcorrelation between efficient replication of cAAV and packaging. This isbest illustrated by comparing replication profiles of pTRT, pBB′.AD andpAD (FIG. 3) and corresponding infectious particle titers (Table 3). NoEGFP-positive cells were found for the other constructs including thenegative control. For clarity, we will use an “AAV” prefix to denotevirus, while prefix “p” to refer to a corresponding plasmid, e.g. AAV.ADis a virus produced by pAD. Virtually no difference between AAV.BB′.ADand AAV.AD titers was found, an observation consistent with a similarefficiency of replication of the corresponding plasmids (compare lanes 4and 8 in FIG. 3). This once again establishes that the BB′ palindrome isdispensable for AAV replication once a switch to a different replicationpathway has occurred.

To examine the structure of packaged AAV.AD genomes, crude lysates wereextensively digested with DNase I, virion DNA was then extracted,resolved on a neutral agarose gel and analyzed using Southern blotting.A 2.2-kb band corresponding in size to ssDNA was released from AAV.ADvirions (not shown). AAV.TRT was included as a positive control. Therewas a slightly higher intensity of AAV.AD ssDNA band compared to that ofAAV.TRT, an observation consistent with a higher yield of AAV.ADinfectious virions compared to the control (Table 3). Thus, the resultestablished that virions produced by pAD indeed contain full-lengthssDNA.

Since AAV.AD contains only a truncated single copy of ITR, the abilityof this domain to target site-specific recombination was tested. Forthis purpose, the method of Palombo et al. (1998) J. Virol.72:5025-50334 was used which is based on PCR amplification of AAV-AAVS1junctions from genomic DNA. To distinguish between unidirectional andbidirectional integration, sets of nested primers were used for both 5′and 3′ ends of the vector sequence. Infections were performed in 293cells in the presence or absence of Rep provided by transient plasmidtransfection. AAV.TRT was included as a positive control.

As shown in FIG. 7, specific DNA bands were amplified from 293 cellsinfected with both AAV.TRT and AAV.AD. The product appears as a smearwith multiple bands, which probably reflects the heterogeneity ofjunction species in a population of transduced cells. Note, that nosignal was detected in mock-infected cells or cells infected withviruses in the absence of Rep. To confirm the nature of the amplifiedproduct, duplicate blots were hybridized with ITR or AAVS1 specificprobes. There is a good correspondence of the hybridization signalsbetween these two blots, further suggesting that the fragments indeedinclude both AAV and AAVS1 sequences. Equally important, this experimentrevealed the ability of AAV.AD genome to integrate in either orientationdespite the polarity of the AD domain in a vector plasmid. The PCRproducts containing both 5′ and 3′ termini of AAV.AD were also subclonedinto pCR2.1 (Invitrogen) and sequenced. While the analysis revealed thepresence of both AAVS1 and AAV.AD sequences in all the clones analyzed,extensive deletions both within the AD domain and the integration sitewere detected (data not shown). This finding, however, is consistentwith other reports on rAAV integration marked by rearrangements of anintegration site and viral termini (Kotin et al. (1992) EMBO J.11:5071-5078; Surosky et al. (1997) J. Virol. 71:7951-7959). Takentogether, these results establish that a single AD domain in the contextof a virion genome serves as an efficient signal for Rep-mediatedsite-specific recombination.

Having identified a minimal ITR sequence that encompasses Rbs, trs andthe D-element as an origin of a novel pathway of AAV replication, othersequences were examined for such elements. One of the best-characterizedRep-binding elements is mapped to the AAV endogenous P5 promoter. The P5promoter has been found to be involved in amplification of integratedRep-Cap sequences in HeLa cells (Chadeuf et al. (2000) J. Gene Med.2:260-268; Nony et al. (2001) J. Virol. 75:9991-9994; Tessier et al.(2001) J. Virol. 75:375-383) as well as to enhance the propagation ofwtAAV itself (Tullis et al. (2000) J. Virol. 75:11511-11521).Considering high homology between the AD domain and the P5 promoter, wespeculated that all these phenomena are examples of the alternativereplication pathway described here. To test this hypothesis, plasmid pP5was created by substituting the 61-bp AD domain in pAD with an 86-bp NlaIII fragment from psub201 (Samulski et al. (1987) J. Virol.61:3096-3101) containing the P5 promoter (nucleotides 238-324 of AAV-2).This element was inserted in a “direct” orientation, i.e. the sameorientation as in psub201. pP5, pC (a negative control) and pAD (apositive control) were transfected into 293 cells along with a fullcomplement of helper functions and then assayed for replication andpackaging.

We were surprised to discover that the replication profile of pP5 wasvirtually indistinguishable from that of pAD (results not shown). Infact, both plasmids replicated exclusively in a circular form and nolinear duplex intermediates were detected. Even more remarkable, pP5 wasa template for packaging as well, albeit approximately 5 fold lessefficiently than pAD. This can be illustrated by comparing functionalAAV titers produced by pAD and pP5 (Table 4). Note that both vectorsdemonstrated a similar level of increase in transduction efficiency by asecondary infection with adenovirus. In summary, the results establishthat cis signals for cAAV replication and packaging are not limited tothe AD domain of the ITR, but may include other homologous sequences,e.g. the P5 promoter.

Gene Therapy

The helper-free defective viral vectors of the present invention can beused to transfer genetic information to any cell, and preferably humancells. However, cells of other mammals, such as rodents, e.g., mice,rats, rabbits, hamsters and guinea pigs; farm animals e.g., sheep,goats, pigs, horses and cows; domestic pets such as cats and dogs,higher primates such as monkeys, and the great apes such baboons,chimpanzees and gorillas can also be cell targets.

The helper-free defective viral vectors of the present invention cancomprise any heterologous nucleic acid of interest preferably thoseencoding proteins. Indeed, any protein can be encoded by a nucleic acidof the defective viral vector. A short list of a few of these proteinsand their roles in particular conditions and/diseases are included inTable 1 below. However, this listing should in no way limit the generalmethodology of the present invention which provides helper-freedefective viral vectors that can comprise any nucleic acid of choice.Furthermore, the helper-free defective viral vectors of the presentinvention can also encode multiple proteins and/or be used in a regimenin which the individual defective viral vectors encode differentproteins.

In one particular example a helper-free defective viral vector of thepresent invention is employed to transduce neurons in vivo to treatParkinson's disease. In this case, the heterologous nucleic acid encodedby the helper-free defective viral vector can be human tyrosinehydroxylase. Therefore, in one embodiment of the present invention, thehelper-free defective viral vectors of the present invention are used todeliver the gene for tyrosine hydroxylase (Genbank HUMTHX, Accession No.M17589) to brain cells. Preferably, a nucleic acid encoding aromaticamino-acid decarboxylase (Genbank HUMDDC, Accession No. M76180) isdelivered in conjunction with the nucleic acid encoding tyrosinehydroxylase. As described previously (U.S. Pat. No. 6,180,613, IssuedJan. 30, 2001, the subject matter of which is hereby incorporated byreference in its entirety) transducing striatal cells with a viralvector to express dopamine synthesizing enzymes may be purely apalliative approach to treating Parkinson's disease, and the underlyingdisease process will continue unabated. Therefore, helper-free defectiveviral vectors of the present invention also can be employed that express“neuroprotective or neurotrophic” factors to prevent furtherdegeneration of dopaminergic neurons and promote regeneration. Thisapproach can include the most specific neurotrophic factor formesencephalic dopaminergic neurons identified to date, glial-derivedneurotrophic factor (GDNF). Other neurotrophic factors of the NGF familyhave previously been expressed from HSV-1 vectors and shown to haveneuroprotective effects. These neurotrophic factors appear to actthrough tyrosine kinase receptors to prevent apoptosis. As theproto-oncogene bcl-2 can prevent neuronal apoptosis in vitro,helper-free defective viral vectors of the present invention thatexpress bcl-2 can also be used to prevent apoptosis in vivo.

Therefore, gene therapy for Parkinson's disease can further involve thedelivery of helper-free defective viral vectors of the present inventioncontaining nucleic acids GDNF (Genbank HUMGDNF02; Accession No. L19063),brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF)(EMBL HSNGF2; Accession No. X53655, and/or other members of theneurotrophin factor family including neurotrophin (NT)-3 (GenbankHUMBDNF; Accession No. M37762) and NT-4 (Genbank HUMPPNT4P; AccessionNo. M86528) as well as additional proteins.

In any case, heterologous nucleic acids are preferably operativelylinked to an expression control sequence (e.g., an early cytomegalusvirus). The present invention can be performed with any such expressioncontrol sequence, but is preferably performed with an expression controlsequence that is obtained from or is a tissue specific promoter (seeU.S. Pat. No. 6,040,172, Issued Mar. 21, 2000, the subject matter ofwhich is hereby incorporated by reference in its entirety). Suchpromoters include the preproenkephalin promoter or the glial fibrillaryacidic protein promoter when a nervous system cell is the target. Otherpromoters include, but are not limited to, the SV40 early promoterregion (Benoist et al. (1981) Nature, 290:304-310), the promotercontained in the 3′ long terminal repeat of Rous sarcoma virus (Yamamotoet al. (1980) Cell, 22:787-797), the herpes thymidine kinase promoter(Wagner et al. (1981) Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), theregulatory sequences of the metallothionein gene (Brinster et al. (1982)Nature 296:39-42); prokaryotic expression vectors such as theβ-lactamase promoter (Villa-Kamaroff et al. (1978) Proc. Natl. Acad.Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer et al. (1983)Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also “Useful Proteins fromRrecombinant Bbacteria”, Scientific American (1980) 242:74-94; promoterelements from yeast or other fungi such as the Gal 4 promoter, the ADC(alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter,alkaline phosphatase promoter; and the animal transcriptional controlregions, which exhibit tissue specificity and have been utilized intransgenic animals: elastase I gene control region which is active inpancreatic acinar cells (Swift et al. (1984) Cell 38:639-646; Ornitz etal. (1986) Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald(1987) Hepatology 7:425-515); insulin gene control region which isactive in pancreatic beta cells (Hanahan (1985) Nature 315:115-122),immunoglobulin gene control region which is active in lymphoid cells(Grosschedl et al. (1984) Cell 38:647-658; Adames et al. (1985) Nature318:533-538; Alexander et al. (1987) Mol. Cell. Biol. 7:1436-1444),mouse mammary tumor virus control region which is active in testicular,breast, lymphoid and mast cells (Leder et al. Cell (1986) 45:485-495),albumin gene control region which is active in liver (Pinkert et al.(1987) Genes and Devel. 1:268-276), alpha-fetoprotein gene controlregion which is active in liver (Krumlauf et al. (1985) Mol. Cell.Biol., 5:1639-1648; Hammer et al. (1987) Science 235:53-58), alpha1-antitrypsin gene control region which is active in the liver (Kelseyet al. (1987) Genes and Devel. 1:161-171), beta-globin gene controlregion which is active in myeloid cells (Mogram et al. (1985) Nature315:338-340; Kollias et al. (1986) Cell 46:89-94), myelin basic proteingene control region which is active in oligodendrocyte cells in thebrain (Readhead et al. (1987) Cell 48:703-712), myosin light chain-2gene control region which is active in skeletal muscle (Sani (1985)Nature 314:283-286), and gonadotropic releasing hormone gene controlregion which is active in the hypothalamus (Mason et al. (1986) Science234:1372-1378).

In addition, the dihydrofolate reductase (DHFR) promoter, as exemplifiedin pED, see Kaufman (1991) Current Protocols in Molecular Biology, 16.12or a glutamine synthetase and/or methionine sulfoximine promoter, suchas pEE14 sold by Celltech can also be employed by the present invention.

In one embodiment, the expression control sequence is a geneticregulatory sequence from an inducible promoter. Novel and generalmethodology for identifying inducible promoter elements (includingtissue-specific promoters) which are responsive to a pulsatileelectromagnetic stimulus and/or a random peptide stimulus has beendescribed in U.S. Ser. No. 60/292,604, filed 22 May 2001, the subjectmatter of which is hereby specifically incorporated by reference in itsentirety. All such genetic regulatory sequences can be employed by thehelper-free defective viral vectors of the present invention eitheralone or in conjunction with other expression control sequences.

The helper-free defective viral vectors of the present invention can bedelivered in vitro, ex vivo and in vivo. As previously exemplified thedelivery can be performed by stereotaxic injection (U.S. Pat. No.6,180,613, Issued Jan. 30, 2001, the subject matter of which is herebyincorporated by reference in its entirety) into the brain for example,or via a guide catheter (U.S. Pat. No. 6,162,796, Issued Dec. 19, 2000,the subject matter of which is hereby incorporated by reference in itsentirety) to an artery to treat the heart. In addition, the helper-freedefective viral vectors of the present invention may also be deliveredintravenously, topically, intracerebro-ventricularly and/orintrathecally, for specific applications. Additional routes ofadministration can be local application of the vector under directvisualization, e.g. superficial cortical application, or othernon-stereotactic applications.

For targeting the vector to a particular type of cell, it may benecessary to associate the vector with a homing agent that bindsspecifically to a surface receptor of the cell. Thus, the vector may beconjugated to a ligand (e.g., enkephalin) for which certain nervoussystem cells have receptors, or a surface specific antibody. Theconjugation may be covalent, e.g., a crosslinking agent such asglutaraldehyde, or noncovalent, e.g., the binding of an avidinatedligand to a biotinylated vector.

In addition, the helper-free defective viral vectors of the presentinvention can be delivered ex vivo, as exemplified by Anderson et al.(U.S. Pat. No. 5,399,346, Issued Mar. 21, 1995, the subject matter ofwhich is hereby incorporated by reference in its entirety).

TABLE 1 PROTEINS INVOLVED IN SPECIFIED CONDITIONS AND DISEASES GENETICDEFECTS DISEASE/SYMPTOM adenosine deaminase severe combinedimmunodeficiency disea

alpha, - antitrypsin pulmonary emphysema 5-alpha reductase malepseudohemaphroditism 17 - alpha reductase male pseudohemaphroditism p53or ARF-P19 proteins linked to cancer insulin insulin-dependent diabetessickle cell anemia B-globin hypoxanthine guanine Lesh-Nyhan Syndronephosphoribosyl-transferase ornithine transcarbamolase Fatal to newbornmales tyrosine hydroxylase Parkinson's disease phenylalanine hydroxylasePhenylketonuria Dralassemia x- or B-globin AT Page 7 A Menkes' syndromeAT Page 7B Wilson Disease hexosamindase A Tay-Sachs Disease acidcholesterylester hydrolase Wolmon Disease

indicates data missing or illegible when filed

Ribozymes and Antisense

In one embodiment of the invention, the helper-free defective viralvector of the invention provides an antisense nucleic acid or aribozyme. Antisense nucleic acids are DNA or RNA molecules that arecomplementary to at least a portion of a specific mRNA molecule (SeeWeintraub (1990) Sci. Amer. 262:40-46; Marcus-Sekura (1987) Nucl. AcidRes. 15: 5749-5763; Marcus-Sekura (1988) Anal. Biochem. 172:289-295;Brysch et al. (1994) Cell Mol. Neurobiol. 14:557-568). Preferably, theantisense molecule employed is complementary to a substantial portion ofthe mRNA. In the cell, the antisense molecule hybridizes to that mRNA,forming a double stranded molecule. The cell does not translate an mRNAin this double-stranded form. Therefore, antisense nucleic acidsinterfere with the expression of mRNA into protein. Preferably a DNAantisense nucleic acid is employed since such an RNA/DNA duplex is apreferred substrate for RNase H. Oligomers of greater than about fifteennucleotides and molecules that hybridize to the AUG initiation codonwill be particularly efficient. Antisense methods have been used toinhibit the expression of many genes in vitro (Marcus-Sekura (1988)Anal. Biochem. 172:289-295; Hambor et al. (1988) Proc. Natl. Acad. Sci.U.S.A. 85:4010-4014) and in situ (Arima et al. (1998) Antisense Nucl.Acid Drug Dev. 8:319-327; Hou et al. (1998) Antisense Nucl. Acid DrugDev. 8:295-308).

Ribozymes are RNA molecules possessing the ability to specificallycleave other single stranded RNA molecules in a manner somewhatanalogous to DNA restriction endonucleases. Ribozymes were discoveredfrom the observation that certain mRNAs have the ability to excise theirown introns. By modifying the nucleotide sequence of these ribozymes,researchers have been able to engineer molecules that recognize specificnucleotide sequences in an RNA molecule and cleave it (Cech (1988) JAMA,260:3030-3034; Cech (1989) Biochem. Intl. 18:7-14). Because they aresequence-specific, only mRNAs with particular sequences are inactivated.

Investigators have identified two types of ribozymes, Tetrahymena-typeand “hammerhead”-type (Haselhoff et al. (1988) Nature 334:585-591).Tetrahymena-type ribozymes recognize four-base sequences, while“hammerhead”-type recognize eleven- to eighteen-base sequences. Thelonger the recognition sequence, the more likely it is to occurexclusively in the target mRNA species. Therefore, hammerhead-typeribozymes are preferable to Tetrahymena-type ribozymes for inactivatinga specific mRNA species, and eighteen base recognition sequences arepreferable to shorter recognition sequences.

When it is desired to place a specific antisense nucleic acid orribozyme into a cell, tissue or animal subject, the heterologous nucleicof interest can be that specific antisense nucleic acid or ribozyme.Therefore, such an antisense nucleic acid or ribozyme can be included ina helper free defective viral vector of the present invention. Such ahelper free defective viral vector can be used to specifically prevent acell, tissue or animal subject from expressing a particular protein. Thecell, tissue or non-human animal subject can then be used to determinethe role of that protein.

In one embodiment, a protein involved in a disease state is selected andthe cell, tissue or non-human animal subject can be used in drug screensfor identifying compounds that can compensate for the loss of thatprotein. For example, classical phenylketonuria (PKU) is due to the lossphenylalanine hydroxylase activity. Therefore, compounds andpeptidomimetics can be tested using liver cells, liver tissue slices,and/or non-human animal subjects in which a defective viral vector ofthe present invention containing an antisense nucleic acid or a ribozymethat prevents phanylalanine hydroxylase expression has beenadministered.

Alternatively, an antisense nucleic acid or ribozyme that prevents theexpression of xanthine oxidase can be administered to a patient withgout, since the xanthine oxidase-dependent conversion of xanthine touric acid is the cause of gout. Similarly, an antisense nucleic acid orribozyme that prevents the expression of tumor necrosis factor alpha canbe administered to a patient in septic shock, or one that has leprosy ortuberculosis. In this case, the fact that the treatment may not lead to100% inhibition of tumor necrosis factor alpha expression may bebeneficial, since most of the detrimental effects due to tumor necrosisfactor alpha is due to it over-expression.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use the therapeutic methods of the invention and compounds andpharmaceutical compositions, and are not intended to limit the scope ofwhat the inventors regard as their invention. Efforts have been made toensure accuracy with respect to numbers used (e.g., amounts,temperature, etc.) but some experimental errors and deviations should beaccounted for. Unless indicated otherwise, parts are parts by weight,molecular weight is average molecular weight, temperature is in degreesCentigrade, and pressure is at or near atmospheric.

Example 1 Production of Helper-Free dAAV Vectors

An hygromycin-sensitive cell line was obtained that expresses the ICP4gene product. A hygromycin resistant plasmid containing the Epstein-BarrVirus (EBV) origin of replication and the EBNA gene was constructed soas to contain two essential AAV genes, Rep and Cap. This plasmid wasthen introduced into this cell line. A cell line expressing Rep/Cap andICP4 was created (i.e., Rep+/Cap+/ICP4+ cells) by selecting cells thatwere hygromycin resistant. A second cell line was prepared in ananalogous manner except the cell line did not express ICP4 (i.e.,Rep+/Cap+/ICP4− cells).

Rep/Cap are expressed at low levels in the absence of adenovirussequences, so they are stable within the cell prior to infection. Boththe Rep+/Cap+/ICP4+ cells and the Rep+/Cap+/ICP4− cells were used in thestudy below.

A defective helper vector was prepared from an HSV virus having adeletion in both copies of the ICP4 gene. Into this viral vector acassette consisting of 5 adenovirus (Ad) genes: E1A, E1B, E2a, E4orf6,and VAI RNA can be inserted. These are the minimal genes necessary forAAV packaging from an adenovirus vector. The resulting “dHSV/Ad helpervector” produces more defective helper vector when re-infected intocells that express the ICP4 gene product.

A defective AAV vector encoding green fluorescent protein (dAAVGFP), wasused to transfect the Rep+/Cap+/ICP4+ cells. After co-infection with thedHSV/Ad helper vector (described above), a mixed production stock ofpackaged dAAVGFP and dHSV/Ad helper vector was produced. This stock wasrepeatedly re-infected into the Rep+/Cap+/ICP4+ cells, readily yieldingincreasingly larger quantities of the mixed production stock. When thetiter was optimized, packaged dAAVGFP free of detectable dHSV/Ad helpervector was produced by passing the production stock through theRep+/Cap+/ICP4− cells. Proof that the helper vectors is removed from thefinal stock of defective viral vectors can be provided by the inclusionof a marker gene in the helper vector which is not included in thedefective viral vector, e.g., luciferase or when it is excluded from thedvv, green fluorescent protein. The expression of the marker protein inthe final stock of packaged defective viral vector can then be performedby assaying for the marker protein. In addition, and/or alternatively,Southern blots can be performed, and/or PCR analyses and/or the use ofspecific antibodies to a protein expressed by the defective helpervirus.

Example 2 Production of Helper-Free “Gutless” Ad Vectors

The identical dHSV/Ad helper vector disclosed above, in Example 1 wasused with a different cell line for packaging a “gutless” adenovirus(Ad) vector. The gutless Ad vector contains adenovirus termini(harboring origins of DNA replication) and a packaging signal, but noother adenovirus genes.

A cell line was created which contains a subset of the adenovirus genomeinserted into the EBV/EBNA plasmid as described in Example 1 above, tocreate a stable cell line. These adenovirus sequences contain theadenovirus genome with the E1A, E1B, E2a, E4orf6, and VAI RNA sequencesdeleted. The deletions were performed in a manner which eliminated anyoverlap with sequences in the dHSV/Ad helper vector and thereby preventany possible homologous recombination between the two. In order toretain the essential fiber protein in the cell line, the fiber gene wascloned by PCR, and after deletion of the E4 and part of E3 sequences(which necessarily eliminated the fiber gene), the fiber gene sequenceswere reinserted next to the remaining E3 sequences. These adenoviralsequences were introduced into cells expressing the ICP4 gene, and theresulting cell line was stable since the adenovirus functions within thecell line were not significantly expressed without the 5 genes that hadbeen removed. When these five genes were re-supplied to the cells viathe dHSV/Ad helper vector described in Example 1 above, all functionsnecessary for adenovirus replication and packaging were present withinthe cell.

A “gutless” adenovirus encoding green fluorescent protein (gutlessAd-GFP), was then co-transfected into the cells. The gutless Ad-GFP wasthen replicated and packaged along with the dHSV/Ad helper vector. Theresulting stock was repeatedly re-infected onto the ICP4/Ad cell line,resulting in increasingly larger mixed stocks in manner identical tothat described above for dAAV production of Example 1. As in the processof Example 1, a second cell line was created with the indicatedadenoviral sequences, but without ICP4. When infected with theproduction stock, this cell line yielded pure gutless Ad-GFP withoutcontamination by other adenovirus or HSV/Ad helper vector.

In a variation of this methodology, the additional adenovirus sequencescontained within the cell line (see above) can alternatively be suppliedby a second amplicon plasmid, which could be packaged as part of thehelper mix along with the amplicon harboring the adenovirus early genes.In still another embodiment, all necessary adenovirus sequences can beinserted into a single amplicon, without any adenovirus packagingsignals or origins or replication, and this is packaged into a “helper”amplicon which can autonomously support packaging of gutless Ad-GFP orany other “gutless” adenovirus vector. In this embodiment, only ICP4positive and ICP4 negative cell lines are necessary for generatingproduction and vector stocks, respectively.

Example 3 Construction of Cell Lines

One of the most efficient means of producing recombinant AAV, in theorywould be to employ a packaging cell line. Unfortunately, heretofore,development of such a cell line has been limited due to the toxicity ofthe genes required for AAV replication and virion assembly. As disclosedherein, these genes include the AAV rep and cap genes and the adenovirustranscription units: E1A, E2a, E4orf6 and VA RNA.

The prospects of producing a cell line with a minimal complement ofgenes appeared to improve with the report that only a subset of thesegenes (rep, cap, E1 and E4orf6) were sufficient for the generation ofhigh AAV titers (Allen et al. (2000) Mol. Ther. 1(1): 88-95). However,despite extensive efforts, these results could not be confirmed. Indeed,when the rep, cap and E4orf6 coding regions were placed under thecontrol of heterologous promoters, a very poor rAAV titer was obtained(about 0.006 IU/cell).

Importantly, the addition of a plasmid expressing VA RNA resulted in analmost 2-fold increased yield of the vector, whereas the addition of aconstruct expressing the E2a construct increased the yield over 6 fold.Furthermore, supplementation with both the VA RNA and E2a genesunexpectedly, led to an over 30-fold increase in rAAV vector production.This titer is comparable to titers obtained using standard helperadenovirus or adenovirus helper plasmid systems.

These data demonstrate that to obtain maximal rAAV titers, all of theseabove-identified adenovirus helper functions should be included, i.e.,Rep, Cap, E1A, (and preferably E1B), E2a, E4orf6, and VA RNA. Inaddition, these results show that the promoters used in conjunction withthese coding regions can be freely substituted since these results wereobtained with heterologous regulatory sequences rather than the nativepromoters for the viral genes. Indeed, the promoters listed throughoutthe specification only serve to exemplify potential alternative choices.

In an attempt to construct a cell line that would harbor all AAV andadenovirus genes necessary for optimal rAAV propagation two plasmidswere constructed. In one of them, the bidirectional tet-responsivepromoter (Clonetech) drives the expression of cap and E4orf6 codingregions, which are followed by beta-globin and SV40 polyadenylationsignals, respectively. This particular cell line also includes the VAIRNA sequence with its native promoter. Incorporation of the hygromycinresistance gene was used to allow selection of stable clones inmammalian cells. The second construct includes the E2a gene placed underthe control of the tet-responsive promoter as well as the rep codingsequence driven by the human metallothionein IIA promoter both followedby SV40 polyadenylation signals. Both plasmids were co-transfected intoTet-On (i.e., Tet inducible) 293 cells (Clonetech). Stable clones wereestablished under hygromycin selection. These cells also constitutivelyexpress E1 gene products. Upon induction with doxycyclin, these cellsexpress Cap, E4orf6 and E2a, and upon induction with Zn2+ ions thesesame cells express Rep (because the metallothionein promoter isinducible by Zn2+). Since high concentrations of Rep are known to beboth deleterious for optimal AAV propagation, and to be toxic to thehost cell, this system allows both the survival of the cell line underuninduced conditions as well as provides the independent control of theintracellular amount of Rep through the use of different concentrationsof Zn2+ during vector production. In the absence of the inducers(doxycyclin and Zn2+, as exemplified herein) gene expression from thetransgenes is sufficiently low to allow cell survival and growth. It isclear that alternative inducible promoters having alternative inducerscan be readily substituted for the promoters and inducers exemplifiedherein.

To generate the rAAV vector, the cells are initially transfected on asmall scale with an AAV vector plasmid carrying an expression cassette.After the first round of packaging, the vector seed stock is then usedfor further amplification, thus obviating the need for any furtherplasmid transfections. This 293-based cell line can also growefficiently in suspension, thereby facilitating large scale vectorproduction using bioreactor-based systems.

Example 4 Circular AAV (cAAV) Vectors

Recombinant cAAV constructs were designed that contain serial deletionsin the viral terminal repeats (ITRs) to identify cis-elementsresponsible for this pathway (Table 2). Rep binding site (Rbs) andterminal resolution site (trs) are underlined.

TABLE 2 cAAV Deletion Mutants DELE- TION SEQUENCE C′CCGCCCGGGCAAAGCCCGGGCGT (SEQ ID NO: 1) B/B′ CGGGCGACCTTTGGTCGCCCGGGGCGTCGGGCGACCTTTGGTCGCCCG (SEQ ID NO: 2) ATTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACT-GAGGCGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAA (SEQ ID NO: 3) DAGGAACCCCTAGTGATGGAGCTCCATCACTAGGGGTTCCT (SEQ ID NO: 4) RBsGAGCGAGCGAGCGCGC (SEQ ID NO: 5) trs CCAACT (SEQ ID NO: 6)

pTRT is a cAAV that contains a wild-type circularization point (the TRTdomain), consisting of a single ITR flanked by two D-sequences. pBB′ADhas only one half of the hairpin (BB′) followed by single A- andD-elements. pBB′Atrs is similar to the previous construct but has theD-sequence deleted except for the nucleotides that comprise the terminalresolution site (trs).

pAD contains only A- and D-elements. pAtrs is its derivative that hasmost of the D-element removed while leaving the trs intact. pDtrscontains a single D-sequence and a part of the A-stem to complement trs.pEGFP is a control vector that does not contain any AAV sequences. Allplasmids are approximately 4.6 kb and harbor an EGFP expression cassetteas well as bacterial ampicillin resistance gene and origin ofreplication.

To study replication and packaging of these cAAV constructs, theplasmids were transfected into 293 cells along with AAV and adenovirushelper functions (see above). Replication was examined using Dpn I assayof Hirt extracts followed by Southern hybridization. As expected bothlinear and circular intermediates were observed during pTRT replication,(see Table 3). However, completely unexpectedly, only circular and notlinear genomes were detected during the replication of pBB′AD and pAD.Small levels of replication of the other constructs (pBB′Atrs, pAtrs andpDtrs) were not different from that of the control vector pEGFP. Thesefinding demonstrate that the A- and D-domains are the minimal elementsrequired for cAAV replication.

Employing these findings, a recombinant vector was generated whichcontains the minimal domain sequence, in order to create the first DNAvector based on a linear-replicating virus which can exclusivelyreplicate in a circular fashion. In order to determine possiblefunctional implications of this new vector, virion assembly was assayedby determining functional titers of crude cell lysates. The test wasperformed on 293 cells in the presence or absence of adenovirus. Thecells were scored 24 hours post-infection. As shown in Table 2, pBB′ADand pAD but not the other cAAV constructs were packaged into infectiousvirions. Importantly, while adenovirus coinfection increased AAVtransduction in all cases, the level of enhancement was 8 times lowerfor AAV.BB′AD and AAV.AD than that for the positive control pTRT. Thisdemonstrates that this new vector provides more efficient transductionwithout assistance of adenovirus, when compared with conventional AAVvectors.

TABLE 3 Circular AAV Replication and Packaging Linear Circular Adeno-Virus Enhance- repli- repli- virus yield, ment cation cation for a i.uper of expression Con- inter- inter- functional 35-mm by struct mediatesmediates titer assay dish adenovirus pTRT 0 0 0 9.4 × 10⁴ 362 fold  —2.6 × 10² pBB′AD — 0 0 5.4 × 10⁵ 45 fold — 1.2 × 10⁴ pBB′Atrs — — 0 0 —— 0 pAD — 0 0 5.2 × 10⁵ 47 fold — 1.1 × 10⁴ pADtrs — — 0 0 — — 0 pDtrs —— 0 0 — — 0 pEGFP — — 0 0 — — 0

Example 5 cis-Element Directing cAAV Replication and Packaging

Construction of Mutant cAAV Vectors. The structures of recombinant cAAVgenomes are schematically presented in FIG. 1. All plasmids of this setharbor an enhanced green fluorescent protein (EGFP) under the control ofthe CMV promoter (Clonetech), as well as different ITR sequences derivedfrom the TRT domain. pTRT contains an intact TRT element consisting of asingle ITR flanked by two D-sequences (Duan et al. (1999) Virology261:8-14; Musatove et al. (2000) supra). This element was derived from acAAV clone captured using a bacterial trapping technique from cellsduring AAV lytic replication and appears to represent a wild-type ITRcircularization point. pTRT is similar to pTRT.EGFPori describedelsewhere, but contains TRT in a flop orientation, which makes itvirtually indistinguishable from a 165-bp ITR sequence in the plasmidpDD-2 previously described (Xiao et al. (1997) J. Virol. 71:941-948).The original ITR sequence of the corresponding linear vector was derivedfrom psub201 and contains a 13-bp deletion in the A region (Samulski etal. (1987) J. Virol. 61:3096-3101). The TRT domain is identical to theITR junction fragment found in cAAVs assembled during latent infectionin vivo. All the deletion mutants were derived from this construct byreplacing the TRT domain with PCR-amplified fragments containingdifferent ITR elements. pBB′.AD has only one half of the hairpin BB′ and5 by of the hairpin CC′ followed by single A- and D-elements. pBB′.Atrsis similar to the previous construct but has the D-sequence deleted,except for the nucleotides that comprise the trs. pAD contains only A-and D-elements. pAtrs is a derivative of pAD, which has most of theD-element removed while leaving the trs intact. pDtrs contains a singleD-sequence and part of the A-stem to complement trs. pC is a controlvector that does not contain any AAV sequence. PCR was performed usinghigh fidelity Advantage Genomic Polymerase Mix (Clonetech) and theintegrity of each construct was confirmed by sequencing. All the cAAVshad the size of a wt virus and were approximately 4.4-4.6 kb in length.This permitted testing of these constructs as templates forrescue-independent packaging. Plasmids 2n (9 kb) and 3n (13.6 kb) werecreated by inserting respectively one or two LacZ-expressing cassettesfrom pCMVbeta (Clonetech) into pAD.

Models of rAAV Propogation. The first model involved co-transfection ofa cis-acting plasmid with a helper plasmid expressing the adenovirusgenes E2A, E4, VA RNA, and AAV Rep and Cap genes (Musatov et al. (2000)supra; Grimm et al. (1998) Hum. Gene Ther. 10:2745-2760; Collaco et al.(1999) Gene 238:397-405). The plasmids (total 2 μg DNA, 1:3 ratio) weretransfected into 70-80% confluent 293 cells (which endogenously expressE1A) in 35-mm culture wells using FuGene 6 (Roche). Cells were harvested72 h post-transfection. This approach represents a helper virus-freerAAV production method.

To ensure that the findings in this study are not limited to this model,a second “classical” method for rAAV production was used as well.Subconfluent 293 cells in 35-mm culture wells were first infected withAd5 (moi 5) for 2 h and then co-transfected with a vector plasmid andpRep.Cap (total 2 μg DNA, 1:2 ratio). The latter contains an XbaI/XbaIfragment from psub201 (33) encoding Rep and Cap proteins. Cells wereharvested when advanced CPE developed, usually 48 h post-transfection.

Isolation of Hirt DNA. Cells seeded in a 35-mm culture well wereharvested, washed with PBS and divided into two equal portions forextraction of extrachromosomal DNA and preparation of virus crudelysates. Low molecular weight DNA was extracted by the Hirt method(1967) J. Mol. Biol. 26:365-369, with minor modifications. Cells wereresuspended in 450 μl of lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mMEDTA, 100 μg/ml proteinase K) and then lysed by adding SDS (0.6% finalconcentration). The reaction was then incubated for 2 h at 37° C. Afterovernight precipitation at 4° C. with 1.1 M NaCl, cellular debris werepelleted at 16,000×g for 30 min and DNA was extracted withphenol:chloroform:isoamyl alcohol (25:24:1) and then chloroform:isoamylalcohol (24:1). Following ethanol precipitation in the presence ofglycogen (30 μg/ml final concentration, Roche), the DNA pellet waswashed with 70% ethanol, dried and resuspended in 40 μl TE buffercontaining DNase-free RNase (1 μg/ml final concentration, Roche).

Preparation AAV crude lysate. The other half of the cells harvested froma 35-mm dish was resuspended in 500 μl of virus lysis buffer (20 mMTris, 150 mM NaCl). Following brief sonication the samples weresubjected to one freeze-thaw cycle. After removal of cell debris bycentrifugation at 3000×g for 10 min, the cleared lysates were stored at−80° C.

Analysis of AAV replication intermediates by Southern blotting. Hirt DNA(10% of total yield from a 35-mm dish) was digested in a 20-μl reactionvolume with various restriction enzymes overnight. Samples were resolvedon a 0.8% agarose gel, transferred to a nylon membrane (Hybond-N+,Amersham) and hybridized to a ³²P-dCTP random-primer-labeled probeagainst the CMV.

Replication of pAD. Terminal resolution site was mutated in pAD as shownin FIG. 1 and the resulting construct pADmut.trs was analyzed forreplication as described above. pAD was included as a positive control.Hirt DNA sample from the experiment described in FIG. 3 and above,corresponding to pAD was digested with XbaI and DpnI with or withoutMboI. DNA was analyzed as described above.

Replication assay for pAD plasmids of different sizes. pAD (4.4 kb), 2n(9 kb) and 3n (13.6 kb) were transfected in equimolar amounts into 293cells together with pAd.Help.Rep.Cap.zeo (ratio 1:3). Hirt DNA wasextracted 72-h post-transfection, digested with a single-cutting enzymeplus DpnI, and separated on a 0.8% agarose gel. Given the fact that allthree constructs contained different numbers of the CMV promoters (one,two or three), the blots were hybridized with a ³²P-labeled probeagainst the unique β-lactamase fragment.

Southern blot analysis of encapsidated AAV genomes. Viral stocks ofAAV.AD and AAV.TRT as a positive control (50% of total yield from a35-mm plate) were extensively digested with DNase I, ssDNA was extractedand separated on a neutral 1% agarose gel. The blot was hybridized witha CMV promoter-specific probe.

Assay for site-specific integration. 293 cells were transfected with aRep-expressing plasmid or pUC19 in 35-mm plates. 6 h post-transfectioncells were washed and infected with AAV.TRT or AAV.AD (20% of totalcrude lysate from a 35-mm dish). In 12 h media was replaced and cellswere incubated for an additional 60 h. Then cells were harvested andgenomic DNA was extracted using Qiagen genomic DNA extraction kit.

Integration of ITR-flanked DNA in the AAVS1 site was determined bynested PCR using primer pairs that flank the 5′ or 3′ end of the rAAVgenome and AAVS1 site chromosome junction. Primers SM 38 (Ori, 3′ end ofrAAV) 5′-TAGTCCTGTCGGGTTTCGCCAC (SEQ ID NO:8); SM 40 (CMV promoter, 5′end of rAAV) 5′-CAAGTGGGCAGTTTACCGTA (SEQ ID NO:9) and SM 33 (AAVS1)5′-GCGCGCATAAGCCAGTAGAG (SEQ ID NO:10) (Palombo et al. (1998) J. Virol.72:5025-5034) were used for the first round of PCR amplification with500 ng of genomic DNA. The reaction was performed using touchdown PCRand HotStar Taq polymerase (Qiagen). One percent of the first reactionwas subjected to a second amplification using nested primers SM 20 (Ori,3′ end of rAAV) 5′-CCACCTCTGACTTGAGCGTC (SEQ ID NO:11) or SM 39 (CMVpromoter, 5′ end of rAAV) 5′-TGGCGTTACTATGGGAACAT (SEQ ID NO:12) and SM34 (AAVS1) 5′-ACAATGGCCAGGGCCAGGCAG (SEQ ID NO:13). Ten percent of theamplification product was resolved on 1.5% agarose gel in duplicates,transferred to a nylon membrane (Hybond-N+, Amersham) and hybridized toAAVS1 or AAV ITR-specific probes. Junction fragments containing both 5′and 3′ parts of rAAV genome were also subcloned into pCR2.1(Invitrogen). Sequencing was performed by The Rockefeller University DNAsequencing laboratory using M13 forward and M13 reverse universalprimers.

TABLE 4 Circular AAV replication and packaging Construct Rfm and Rfd^(a)cAAV^(a) Virus yield^(b) pTRT + + 2.6 × 10² pBB′AD − + 1.2 × 10⁴pBB′Atrs − − 0 pAD − + 1.1 × 10⁴ pADtrs − − 0 pDtrs − − 0 pC − − 0^(a)As determined by Southern blot analysis. ^(b)Total i.u. yield from a35-mm plate.

TABLE 5 Packaging of pP5 Construct Rfm and Rfd^(a) cAAV^(a) Virusyield^(b) pP5 − + 1.9 × 10³ pAD − + 8.0 × 10³ pC − − 0 ^(a)As determinedby Southern blot analysis. ^(b)Total i.u. yield from a 35-mm plate.

1. A nucleotide sequence capable of directing circular adeno-associatedvirus replication, comprising a loop sequence TGGCCAA flanked on the 5′and 3′ sides by complementary sequences, wherein a hairpin structure isformed between the complementary sequences. 2-7. (canceled)
 8. Adefective circular adeno-associated virus-derived vector comprising (i)at least one of the nucleotide sequence of claim 1, and (ii) aheterologous nucleic acid sequence encoding a protein of interest. 9-12.(canceled)
 13. The vector of claim 8, wherein the protein of interest isa therapeutic protein consisting of a protein, an enzyme, or a growthfactor.
 14. The vector of claim 13, wherein the therapeutic protein isinsulin, β-globin, p53, or ARF-P19.
 15. The vector of claim 13, whereinthe therapeutic enzyme is selected from the group consisting ofadenosine deaminase, α-antitrypsin, 5-α reductase, 17-α reductase,hypoxanthine guanine phosphoribosyl transferase, ornithinetranscarbamolase, tyrosine hydroxylase, hexosamindase A, and acidcholesterylester hydrolase.
 16. A method of treating an acute medicalcondition in a subject in need thereof, comprising administering acircular adeno-associated virus (cAAV)-derived vector comprising thenucleotide sequence of claim 1, and a nucleic acid sequence encoding atherapeutic protein of interest operably linked to a promoter sequence,wherein the therapeutic protein is expressed within 1 day afteradministration of the cAAV-derived vector.
 17. The method of claim 16,wherein expression is achieved within 8-24 hours after administration.18. The method of claim 17, wherein expression is achieved within 8-12hours.
 19. The method of claim 18, wherein expression is increased 10fold within 48 hours.
 20. A defective helper vector for use in theproduction of a packaged defective viral vector; wherein the defectivehelper vector: (a) requires the expression and/or transcription of oneor more exogenous nucleic acid(s) to replicate; and (b) comprises one ormore helper heterologous nucleic acid that aids in the replicationand/or packaging of a defective viral vector. 21-30. (canceled)
 31. Amethod for generating a production stock of packaged defective viralvectors (dvv) and packaged defective helper vectors (dhlpv), the methodcomprising placing a defective helper vector and a defective viralvector into a permissive cell, wherein the defective viral vector andthe defective helper vector are replicated and packaged; wherein thedhlpv comprises one or more helper heterologous nucleic acid(s), theexpression and/or transcription of which are necessary but notsufficient for the replication or packaging of the defective viralvector in the permissive cell; and wherein the dhlpv further requiresthe expression and/or transcription of one or more exogenous nucleicacid(s) to replicate and be packaged; wherein the permissive cellcomprises the exogenous nucleic acid(s) required to replicate andpackage the dhlpv, and further comprises one or more ancillaryheterologous nucleic acids, the expression and/or transcription of whichin conjunction with the expression and/or transcription of the helperheterologous nucleic acid(s) enables the replication and/or packaging ofthe defective viral vector in the permissive cell; and wherein aproduction stock of packaged defective helper vector and packageddefective viral vector is generated.
 32. The method of claim 31, whereinthe dvv further comprises a heterologous nucleic acid of interest.
 33. Aproduction stock generated by the method of claim
 31. 34. The method ofclaim 31, wherein the defective helper vector is a herpes simplex virus(HSV); the exogenous nucleic acid is a HSV ICP4 gene, and the helperheterologous nucleic acids are adenoviral genes E1A, E2a, E4orf6, andVAI RNA.
 35. The method of claim 31, wherein the permissive cellcomprises a plasmid that has an Epstein-Barr Viral origin of replicationand encodes ancillary heterologous nucleic acids AAV Rep and Cap; andwherein the cell expresses the exogenous nucleic acid, HSV ICP4.
 36. Amethod of producing a helper-free defective viral vector comprisingco-infecting the production stock of packaged dhlpv and dvv of claim 33into a non-permissive cell; wherein the nonpermissive cell comprises oneor more ancillary heterologous nucleic acids, the expression and/ortranscription of which in conjunction with the expression and/ortranscription of the helper heterologous nucleic acid(s) enables thereplication and/or packaging of the defective viral vector in thenon-permissive cell; but wherein the replication and/or packaging of thedhlpv is prevented because the non-permissive cell does not comprise theexogenous nucleic acid(s).
 37. The method of claim 34, wherein thedefective helper vector is a herpes simplex virus (HSV); the exogenousnucleic acid is the HSV ICP4 gene; the helper heterologous nucleic acidsare the adenoviral genes E1A, E2a, E4orf6, and VAI RNA; the permissivecell comprises a plasmid that has an Epstein-Barr Viral origin ofreplication and encodes the ancillary heterologous nucleic acids AAV Repand Cap.
 38. The helper-free defective viral vector produced by themethod of claim
 36. 39. A non-human mammalian host transformed with thevector of claim
 38. 40. A method of delivering a gene of interest to atarget tissue of an animal subject, comprising administering the vectorof claim 38 to the tissue of the animal subject.
 41. (canceled) 41.(canceled)